1
|
Reynders A, Anissa Jhumka Z, Gaillard S, Mantilleri A, Malapert P, Magalon K, Etzerodt A, Salio C, Ugolini S, Castets F, Saurin AJ, Serino M, Hoeffel G, Moqrich A. Gut microbiota promotes pain chronicity in Myosin1A deficient male mice. Brain Behav Immun 2024; 119:S0889-1591(24)00397-0. [PMID: 38710336 DOI: 10.1016/j.bbi.2024.05.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2023] [Revised: 04/23/2024] [Accepted: 05/03/2024] [Indexed: 05/08/2024] Open
Abstract
Chronic pain is a heavily debilitating condition and a huge socio-economic burden, with no efficient treatment. Over the past decade, the gut microbiota has emerged as an important regulator of nervous system's health and disease states. Yet, its contribution to the pathogenesis of chronic somatic pain remains poorly documented. Here, we report that male but not female mice lacking Myosin1a (KO) raised under single genotype housing conditions (KO-SGH) are predisposed to develop chronic pain in response to a peripheral tissue injury. We further underscore the potential of MYO1A loss-of-function to alter the composition of the gut microbiota and uncover a functional connection between the vulnerability to chronic pain and the dysbiotic gut microbiota of KO-SGH males. As such, parental antibiotic treatment modifies gut microbiota composition and completely rescues the injury-induced pain chronicity in male KO-SGH offspring. Furthermore, in KO-SGH males, this dysbiosis is accompanied by a transcriptomic activation signature in the dorsal root ganglia (DRG) macrophage compartment, in response to tissue injury. We identify CD206+CD163- and CD206+CD163+ as the main subsets of DRG resident macrophages and show that both are long-lived and self-maintained and exhibit the capacity to monitor the vasculature. Consistently, in vivo depletion of DRG macrophages rescues KO-SGH males from injury-induced chronic pain underscoring a deleterious role for DRG macrophages in a Myo1a-loss-of function context. Together, our findings reveal gene-sex-microbiota interactions in determining the predisposition to injury-induced chronic pain and point-out DRG macrophages as potential effector cells.
Collapse
Affiliation(s)
- Ana Reynders
- Aix-Marseille-Université, CNRS, Institut de Biologie du Développement de Marseille, Marseille, France.
| | - Z Anissa Jhumka
- Aix-Marseille-Université, CNRS, Institut de Biologie du Développement de Marseille, Marseille, France
| | | | - Annabelle Mantilleri
- Aix-Marseille-Université, CNRS, Institut de Biologie du Développement de Marseille, Marseille, France
| | - Pascale Malapert
- Aix-Marseille-Université, CNRS, Institut de Biologie du Développement de Marseille, Marseille, France
| | - Karine Magalon
- Aix-Marseille-Université, CNRS, Institut de Biologie du Développement de Marseille, Marseille, France
| | - Anders Etzerodt
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
| | - Chiara Salio
- Department of Veterinary Sciences, University of Turin, Grugliasco, TO, Italy
| | - Sophie Ugolini
- Aix-Marseille-Université, CNRS, INSER, Centre d'Immunologie de Marseille-Luminy, Marseille, France
| | - Francis Castets
- Aix-Marseille-Université, CNRS, Institut de Biologie du Développement de Marseille, Marseille, France
| | - Andrew J Saurin
- Aix-Marseille-Université, CNRS, Institut de Biologie du Développement de Marseille, Marseille, France
| | - Matteo Serino
- Institut de Recherche en Santé Digestive, Université de Toulouse-Paul Sabatier, INSERM, INRAe, ENVT, UPS, Toulouse, France
| | - Guillaume Hoeffel
- Aix-Marseille-Université, CNRS, INSER, Centre d'Immunologie de Marseille-Luminy, Marseille, France
| | - Aziz Moqrich
- Aix-Marseille-Université, CNRS, Institut de Biologie du Développement de Marseille, Marseille, France.
| |
Collapse
|
2
|
Martins M, Serino M, Viana-Machado F, Novais-Bastos H. Management and prognosis of malignant pleural effusions managed with indwelling pleural catheters. J Bras Pneumol 2023; 49:e20230225. [PMID: 38055389 PMCID: PMC10760441 DOI: 10.36416/1806-3756/e20230225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/08/2023] Open
Affiliation(s)
- M Martins
- . Departamento de Pneumologia, Centro Hospitalar Universitário de São João, Porto, Portugal
| | - M Serino
- . Departamento de Pneumologia, Centro Hospitalar Universitário de São João, Porto, Portugal
| | - F Viana-Machado
- . Departamento de Pneumologia, Centro Hospitalar Universitário de São João, Porto, Portugal
| | - H Novais-Bastos
- . Departamento de Pneumologia, Centro Hospitalar Universitário de São João, Porto, Portugal
- . Instituto de Investigação e Inovação em Saúde - i3S - Universidade do Porto, Porto, Portugal
| |
Collapse
|
3
|
Mas-Orea X, Rey L, Battut L, Bories C, Petitfils C, Abot A, Gheziel N, Wemelle E, Blanpied C, Motta JP, Knauf C, Barreau F, Espinosa E, Aloulou M, Cenac N, Serino M, Mouledous L, Fazilleau N, Dietrich G. Proenkephalin deletion in hematopoietic cells induces intestinal barrier failure resulting in clinical feature similarities with irritable bowel syndrome in mice. Commun Biol 2023; 6:1168. [PMID: 37968381 PMCID: PMC10652007 DOI: 10.1038/s42003-023-05542-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Accepted: 11/03/2023] [Indexed: 11/17/2023] Open
Abstract
Opioid-dependent immune-mediated analgesic effects have been broadly reported upon inflammation. In preclinical mouse models of intestinal inflammatory diseases, the local release of enkephalins (endogenous opioids) by colitogenic T lymphocytes alleviate inflammation-induced pain by down-modulating gut-innervating nociceptor activation in periphery. In this study, we wondered whether this immune cell-derived enkephalin-mediated regulation of the nociceptor activity also operates under steady state conditions. Here, we show that chimeric mice engrafted with enkephalin-deficient bone marrow cells exhibit not only visceral hypersensitivity but also an increase in both epithelial paracellular and transcellular permeability, an alteration of the microbial topography resulting in increased bacteria-epithelium interactions and a higher frequency of IgA-producing plasma cells in Peyer's patches. All these alterations of the intestinal homeostasis are associated with an anxiety-like behavior despite the absence of an overt inflammation as observed in patients with irritable bowel syndrome. Thus, our results show that immune cell-derived enkephalins play a pivotal role in maintaining gut homeostasis and normal behavior in mice. Because a defect in the mucosal opioid system remarkably mimics some major clinical symptoms of the irritable bowel syndrome, its identification might help to stratify subgroups of patients.
Collapse
Affiliation(s)
- Xavier Mas-Orea
- IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Lea Rey
- IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Louise Battut
- IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Cyrielle Bories
- INFINITy, Université de Toulouse, INSERM U1291, CNRS U5051, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Camille Petitfils
- IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Anne Abot
- IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
- Enterosys SAS, Labège, France
| | - Nadine Gheziel
- IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
- INFINITy, Université de Toulouse, INSERM U1291, CNRS U5051, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Eve Wemelle
- IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Catherine Blanpied
- IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Jean-Paul Motta
- IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Claude Knauf
- IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Frederick Barreau
- IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Eric Espinosa
- IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Meryem Aloulou
- INFINITy, Université de Toulouse, INSERM U1291, CNRS U5051, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Nicolas Cenac
- IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Matteo Serino
- IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Lionel Mouledous
- Research Center on Animal Cognition (CRCA), Center of Integrative Biology (CBI), Université de Toulouse, CNRS UMR-5169, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Nicolas Fazilleau
- INFINITy, Université de Toulouse, INSERM U1291, CNRS U5051, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Gilles Dietrich
- IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France.
| |
Collapse
|
4
|
Petitfils C, Maurel S, Payros G, Hueber A, Agaiz B, Gazzo G, Marrocco R, Auvray F, Langevin G, Motta JP, Floch P, Tremblay-Franco M, Galano JM, Guy A, Durand T, Lachambre S, Durbec A, Hussein H, Decraecker L, Bertrand-Michel J, Saoudi A, Oswald E, Poisbeau P, Dietrich G, Melchior C, Boeckxstaens G, Serino M, Le Faouder P, Cenac N. Identification of bacterial lipopeptides as key players in IBS. Gut 2022; 72:939-950. [PMID: 36241390 PMCID: PMC10086498 DOI: 10.1136/gutjnl-2022-328084] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Accepted: 09/27/2022] [Indexed: 12/08/2022]
Abstract
OBJECTIVES Clinical studies revealed that early-life adverse events contribute to the development of IBS in adulthood. The aim of our study was to investigate the relationship between prenatal stress (PS), gut microbiota and visceral hypersensitivity with a focus on bacterial lipopeptides containing γ-aminobutyric acid (GABA). DESIGN We developed a model of PS in mice and evaluated, in adult offspring, visceral hypersensitivity to colorectal distension (CRD), colon inflammation, barrier function and gut microbiota taxonomy. We quantified the production of lipopeptides containing GABA by mass spectrometry in a specific strain of bacteria decreased in PS, in PS mouse colons, and in faeces of patients with IBS and healthy volunteers (HVs). Finally, we assessed their effect on PS-induced visceral hypersensitivity. RESULTS Prenatally stressed mice of both sexes presented visceral hypersensitivity, no overt colon inflammation or barrier dysfunction but a gut microbiota dysbiosis. The dysbiosis was distinguished by a decreased abundance of Ligilactobacillus murinus, in both sexes, inversely correlated with visceral hypersensitivity to CRD in mice. An isolate from this bacterial species produced several lipopeptides containing GABA including C14AsnGABA. Interestingly, intracolonic treatment with C14AsnGABA decreased the visceral sensitivity of PS mice to CRD. The concentration of C16LeuGABA, a lipopeptide which inhibited sensory neurons activation, was decreased in faeces of patients with IBS compared with HVs. CONCLUSION PS impacts the gut microbiota composition and metabolic function in adulthood. The reduced capacity of the gut microbiota to produce GABA lipopeptides could be one of the mechanisms linking PS and visceral hypersensitivity in adulthood.
Collapse
Affiliation(s)
- Camille Petitfils
- IRSD, Université de Toulouse-Paul Sabatier, INSERM, INRAe, ENVT, UPS, Toulouse, France
| | - Sarah Maurel
- IRSD, Université de Toulouse-Paul Sabatier, INSERM, INRAe, ENVT, UPS, Toulouse, France
| | - Gaelle Payros
- IRSD, Université de Toulouse-Paul Sabatier, INSERM, INRAe, ENVT, UPS, Toulouse, France
| | - Amandine Hueber
- Lipidomic, MetaboHUB-MetaToul, National Infrastructure of Metabolomics and Fluxomics, Toulouse, France.,I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Bahija Agaiz
- IRSD, Université de Toulouse-Paul Sabatier, INSERM, INRAe, ENVT, UPS, Toulouse, France
| | - Géraldine Gazzo
- Institut des Neurosciences Cellulaire et Integrative (INCI), Centre National de la Recherche Scientifique, Université de Strasbourg, Strasbourg, France
| | - Rémi Marrocco
- INFINITY, Université de Toulouse-Paul Sabatier, INSERM, CNRS, UPS, Toulouse, France
| | - Frédéric Auvray
- IRSD, Université de Toulouse-Paul Sabatier, INSERM, INRAe, ENVT, UPS, Toulouse, France
| | - Geoffrey Langevin
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, Université de Montpellier, ENSCM, Montpellier, France
| | - Jean-Paul Motta
- IRSD, Université de Toulouse-Paul Sabatier, INSERM, INRAe, ENVT, UPS, Toulouse, France
| | - Pauline Floch
- IRSD, Université de Toulouse-Paul Sabatier, INSERM, INRAe, ENVT, UPS, Toulouse, France.,Service de bactériologie-hygiène, CHU Toulouse, Hôpital Purpan, Toulouse, France
| | - Marie Tremblay-Franco
- Toxalim (Research Center in Food Toxicology), Toulouse University, INRAE, ENVT, INP-Purpan, UPS, Toulouse, France.,Metatoul-AXIOM Platform, MetaboHUB, Toxalim, INRAE, Toulouse, France
| | - Jean-Marie Galano
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, Université de Montpellier, ENSCM, Montpellier, France
| | - Alexandre Guy
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, Université de Montpellier, ENSCM, Montpellier, France
| | - Thierry Durand
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, Université de Montpellier, ENSCM, Montpellier, France
| | - Simon Lachambre
- INFINITY, Université de Toulouse-Paul Sabatier, INSERM, CNRS, UPS, Toulouse, France
| | - Anaëlle Durbec
- Lipidomic, MetaboHUB-MetaToul, National Infrastructure of Metabolomics and Fluxomics, Toulouse, France.,I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Hind Hussein
- Laboratory of Intestinal Neuro-immune Interaction, Translational Research Center for Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium
| | - Lisse Decraecker
- Laboratory of Intestinal Neuro-immune Interaction, Translational Research Center for Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium
| | - Justine Bertrand-Michel
- Lipidomic, MetaboHUB-MetaToul, National Infrastructure of Metabolomics and Fluxomics, Toulouse, France.,I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Abdelhadi Saoudi
- INFINITY, Université de Toulouse-Paul Sabatier, INSERM, CNRS, UPS, Toulouse, France
| | - Eric Oswald
- IRSD, Université de Toulouse-Paul Sabatier, INSERM, INRAe, ENVT, UPS, Toulouse, France.,Service de bactériologie-hygiène, CHU Toulouse, Hôpital Purpan, Toulouse, France
| | - Pierrick Poisbeau
- Institut des Neurosciences Cellulaire et Integrative (INCI), Centre National de la Recherche Scientifique, Université de Strasbourg, Strasbourg, France
| | - Gilles Dietrich
- IRSD, Université de Toulouse-Paul Sabatier, INSERM, INRAe, ENVT, UPS, Toulouse, France
| | - Chloe Melchior
- Gastroenterology Department, Rouen University Hospital, Rouen, France.,Institute for Research and Innovation in Biomedicine, INSERM CIC-CRB 1404, INSERM UMR 1073, Normandy University, Rouen, France.,Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Guy Boeckxstaens
- Laboratory of Intestinal Neuro-immune Interaction, Translational Research Center for Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium
| | - Matteo Serino
- IRSD, Université de Toulouse-Paul Sabatier, INSERM, INRAe, ENVT, UPS, Toulouse, France
| | - Pauline Le Faouder
- Lipidomic, MetaboHUB-MetaToul, National Infrastructure of Metabolomics and Fluxomics, Toulouse, France.,I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Nicolas Cenac
- IRSD, Université de Toulouse-Paul Sabatier, INSERM, INRAe, ENVT, UPS, Toulouse, France
| |
Collapse
|
5
|
Trovisco R, Freitas C, Serino M, Ferreira P, Martins B, Coelho D, Melo N, Fernandes G, Magalhães A, Bastos HN. Predictors of lung entrapment in malignant pleural effusion. Pulmonology 2022:S2531-0437(22)00199-4. [PMID: 36180353 DOI: 10.1016/j.pulmoe.2022.08.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Revised: 07/25/2022] [Accepted: 08/03/2022] [Indexed: 11/23/2022] Open
Abstract
INTRODUCTION Malignant pleural effusion (MPE) is a common complication in advanced stages of malignancy and is associated with poor prognosis. Non-expandable lung (NEL) often occurs and its presence influences the MPE approach. Our main objective was to assess risk factors for malignant NEL. METHODS Patients diagnosed with pathologically confirmed MPE between January 2012 and December 2018 in our institution were retrospectively analyzed. Demographic and clinical data of patients were reviewed and compared according to the presence or absence of NEL. A univariate and multivariate binary logistic regression analysis were used to determine predictors of the development of NEL. RESULTS Of 365 patients included, 68 (18.6%) had NEL. After multivariate analysis, we found that loculated MPE (OR 8.63, 95%CI 4.30-17.33, p<0.001), complete hemithorax opacification (OR 2.81, 95%CI 1.17-6.76, p<0.021), lung cancer (OR 2.09, 95%CI 1.01-4.31, p=0.047) and higher effusion-serum LDH ratio (OR 1.09, 95%CI 1.00-1.17, p=0.039) were independent predictors of malignant NEL. There were no significant differences compared with expandable lung group regarding time from primary malignancy diagnosis to MPE diagnosis (3.0, IQR 0.0-75.8 vs 2.0, IQR 0.0-75.5 weeks, p=0.942) or MPE symptoms onset to MPE diagnosis (4.0, IQR 1.0-9.0 vs 3.0, IQR 1.0-9.0 weeks, p=0.497). Patients with NEL had a higher number of therapeutic pleural drainages (3.0, IQR 2.0-6.0 vs 2.0, IQR 1.0-3.0; p<0.001) and longer hospital stay (32.5, IQR 15.5-46.3 vs 21.0, IQR 11.0-36.0, p=0.007), measured in hospitalization days until the end of life, than patients with expandable lung. The rate of recurrence of pleural effusion was not significantly different between groups (p=0.291). Overall survival (OS) was 3.0 (95%CI, 2.3-3.7) months, regardless of lung expandability (p=0.923). CONCLUSION Loculated MPE, complete hemithorax opacification, lung cancer and a higher effusion-serum LDH ratio were found to be independent predictors for NEL. These patients underwent thoracocenteses more frequently and had longer hospitalization days, although without significant impact in the OS.
Collapse
Affiliation(s)
- R Trovisco
- Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro, 4200-319 Porto, Portugal
| | - C Freitas
- Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro, 4200-319 Porto, Portugal; Department of Pulmonology, Centro Hospitalar e Universitário São João, Porto, Portugal
| | - M Serino
- Department of Pulmonology, Centro Hospitalar e Universitário São João, Porto, Portugal
| | - P Ferreira
- Department of Pulmonology, Centro Hospitalar e Universitário São João, Porto, Portugal
| | - B Martins
- Department of Pulmonology, Centro Hospitalar e Universitário São João, Porto, Portugal
| | - D Coelho
- Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro, 4200-319 Porto, Portugal; Department of Pulmonology, Centro Hospitalar e Universitário São João, Porto, Portugal
| | - N Melo
- Department of Pulmonology, Centro Hospitalar e Universitário São João, Porto, Portugal
| | - G Fernandes
- Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro, 4200-319 Porto, Portugal; Department of Pulmonology, Centro Hospitalar e Universitário São João, Porto, Portugal
| | - A Magalhães
- Department of Pulmonology, Centro Hospitalar e Universitário São João, Porto, Portugal
| | - H N Bastos
- Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro, 4200-319 Porto, Portugal; Department of Pulmonology, Centro Hospitalar e Universitário São João, Porto, Portugal; Institute for Research and Innovation in Health, University of Porto, Rua Alfredo Allen, 208, 4200-136 Porto, Portugal.
| |
Collapse
|
6
|
Serino M, Freitas C, Martins M, Ferreira P, Cardoso C, Veiga F, Santos V, Araújo D, Novais-Bastos H, Magalhães A, Queiroga H, Fernandes G, Hespanhol V. Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors. Pulmonology 2022:S2531-0437(22)00076-9. [PMID: 35414494 DOI: 10.1016/j.pulmoe.2022.03.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2021] [Revised: 03/14/2022] [Accepted: 03/14/2022] [Indexed: 10/18/2022] Open
Abstract
OBJECTIVE To identify predictors of immune-related adverse events (IRAEs) in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). Assess associations between outcomes and the development of IRAEs. METHODS Retrospective analysis of patients with NSCLC treated with ICIs between 2016 and 2020 in the Pulmonology Department of our hospital. Patients with and without IRAEs were compared. A logistic regression analysis was performed to determine predictors of IRAEs. Progression-free survival (PFS) and overall survival (OS) curves were calculated using the Kaplan-Meier method, and the long-rank test was used to assess survival differences between groups. Univariate and multivariate Cox proportional-hazards regression models were used to identify factors associated with PFS and OS. The value considered statistically significant was p≤0.05. RESULTS A total of 184 patients (77.7% men, mean age 66.9±9.5 years) treated with ICIs were analyzed. During follow-up, 49 (26.6%) patients developed IRAEs and 149 (81.0%) died. According to the multivariate logistic regression analysis, treatment with statins (OR:3.15; p = 0.007), previous systemic corticosteroid therapy (OR:3.99; p = 0.001), disease controlled as response to ICI (OR:5.93; p < 0.001) and higher hemoglobin values (OR:1.28; p = 0.040) were independent predictors for the development of IRAEs. Patients who developed IRAEs had significantly longer medians of PFS (41.0 vs 9.0 weeks, p < 0.001) and OS (89.0 vs 28.0 weeks; p < 0.001). CONCLUSIONS Patients treated with statins, pre-ICI systemic corticosteroids, higher baseline hemoglobin value and controlled disease as initial response to ICI had a higher risk of developing IRAEs. The development of IRAEs was associated with better outcomes.
Collapse
Affiliation(s)
- M Serino
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal.
| | - C Freitas
- Pulmonology Department, Centro Hospitalar Universitário São João; Faculty of Medicine, University of Porto, Porto, Portugal
| | - M Martins
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal
| | - P Ferreira
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal
| | - C Cardoso
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal
| | - F Veiga
- Faculty of Medicine, University of Porto, Porto, Portugal
| | - V Santos
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal
| | - D Araújo
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal
| | - H Novais-Bastos
- Pulmonology Department, Centro Hospitalar Universitário São João; Faculty of Medicine, University of Porto, Porto, Portugal
| | - A Magalhães
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal
| | - H Queiroga
- Pulmonology Department, Centro Hospitalar Universitário São João; Faculty of Medicine, University of Porto, Porto, Portugal
| | - G Fernandes
- Pulmonology Department, Centro Hospitalar Universitário São João; Faculty of Medicine, University of Porto, Porto, Portugal
| | - V Hespanhol
- Pulmonology Department, Centro Hospitalar Universitário São João; Faculty of Medicine, University of Porto, Porto, Portugal
| |
Collapse
|
7
|
Gebrayel P, Nicco C, Al Khodor S, Bilinski J, Caselli E, Comelli EM, Egert M, Giaroni C, Karpinski TM, Loniewski I, Mulak A, Reygner J, Samczuk P, Serino M, Sikora M, Terranegra A, Ufnal M, Villeger R, Pichon C, Konturek P, Edeas M. Microbiota medicine: towards clinical revolution. J Transl Med 2022; 20:111. [PMID: 35255932 PMCID: PMC8900094 DOI: 10.1186/s12967-022-03296-9] [Citation(s) in RCA: 74] [Impact Index Per Article: 37.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Accepted: 02/03/2022] [Indexed: 02/07/2023] Open
Abstract
The human gastrointestinal tract is inhabited by the largest microbial community within the human body consisting of trillions of microbes called gut microbiota. The normal flora is the site of many physiological functions such as enhancing the host immunity, participating in the nutrient absorption and protecting the body against pathogenic microorganisms. Numerous investigations showed a bidirectional interplay between gut microbiota and many organs within the human body such as the intestines, the lungs, the brain, and the skin. Large body of evidence demonstrated, more than a decade ago, that the gut microbial alteration is a key factor in the pathogenesis of many local and systemic disorders. In this regard, a deep understanding of the mechanisms involved in the gut microbial symbiosis/dysbiosis is crucial for the clinical and health field. We review the most recent studies on the involvement of gut microbiota in the pathogenesis of many diseases. We also elaborate the different strategies used to manipulate the gut microbiota in the prevention and treatment of disorders. The future of medicine is strongly related to the quality of our microbiota. Targeting microbiota dysbiosis will be a huge challenge.
Collapse
|
8
|
Serino M, Cardoso C, Carneiro RJ, Ferra J, Aguiar F, Rodrigues D, Redondo M, van Zeller M, Drummond M. OSA patients not treated with PAP - Evolution over 5 years according to the Baveno classification and cardiovascular outcomes. Sleep Med 2021; 88:1-6. [PMID: 34710706 DOI: 10.1016/j.sleep.2021.09.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2021] [Revised: 08/21/2021] [Accepted: 09/13/2021] [Indexed: 11/28/2022]
Abstract
INTRODUCTION The evolution of patients with obstructive sleep apnea (OSA) non-eligible for PAP-therapy at diagnosis is unknown. Currently, the severity of OSA is based on the apnea-hypopnea index (AHI), but its prognostic relevance has raised concerns. The Baveno classification may allow a better stratification of severity and therapeutic guidance in OSA. METHODS Patients with AHI≥5/h in 2015, classified into Baveno groups A and B and non-eligible for PAP therapy at diagnosis and over 5 years, were analyzed. Patients were reclassified into Baveno groups (A-D) and changes in groups over 5 years were explored. Patients in Baveno groups C and D, who developed major cardiovascular comorbidities (CVC) or end-organ damage (EOD group), were compared with patients in Baveno groups A and B (non-EOD group). To identify predictors of the development of major CVC or EOD, a logistic regression analysis was performed. RESULTS There were 76 patients, 58% male, mean age 51.9 ± 10.1 years, mean body mass index (BMI) of 30.3 ± 5.0 kg/m2 and median AHI of 8.9 (5.9-12.0) events/h. At diagnosis, 46% and 54% of patients were classified into Baveno group A and group B, respectively. In total, 21% of patients developed major CVC or EOD (Baveno group C or D); higher age (p = 0.011) and BMI (p = 0.004) and a higher percentage of central apneas (p = 0.012) at diagnosis significantly predicted it, while sex, sleepiness, insomnia, AHI, ODI and T90 were not. CONCLUSIONS A significant percentage of patients non-eligible for PAP-therapy at diagnosis of OSA developed CVC or EOD; higher age and BMI and a higher percentage of central apneas were significant predictors.
Collapse
Affiliation(s)
- M Serino
- Department of Pneumology, Centro Hospitalar São João, Porto, Portugal.
| | - C Cardoso
- Department of Pneumology, Centro Hospitalar São João, Porto, Portugal
| | - R J Carneiro
- Department of Pneumology, Centro Hospitalar Oeste, Hospital Torres Vedras, Torres Vedras, Portugal
| | - J Ferra
- Department of Pneumology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, LisboaVedras, Portugal
| | - F Aguiar
- Department of Pneumology, Hospital de Braga, Braga, Portugal
| | - D Rodrigues
- Pulmonology Department, Centro Hospitalar Universitário São João, Sleep and Non-Invasive Ventilation Unit, Centro Hospitalar Universitário São João, Porto, Portugal
| | - M Redondo
- Pulmonology Department, Centro Hospitalar Universitário São João, Sleep and Non-Invasive Ventilation Unit, Centro Hospitalar Universitário São João, Porto, Portugal
| | - M van Zeller
- Sleep and Non-Invasive Ventilation Unit, Centro Hospitalar Universitário São João, Faculty of Medicine, University of Porto, Porto, Portugal
| | - M Drummond
- Sleep and Non-Invasive Ventilation Unit, Centro Hospitalar Universitário São João, Faculty of Medicine, University of Porto, Porto, Portugal
| |
Collapse
|
9
|
Serino M, Pinto J, van Zeller M, Drummond M. Phone medical appointments for sleep-disordered breathing in Covid-19 pandemic - were they useful? Sleep Med 2021; 86:123. [PMID: 34127389 PMCID: PMC8168330 DOI: 10.1016/j.sleep.2021.05.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Accepted: 05/24/2021] [Indexed: 11/17/2022]
Affiliation(s)
- M Serino
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal.
| | - J Pinto
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal.
| | - M van Zeller
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal; Sleep and Non-Invasive Ventilation Unit, Centro Hospitalar Universitário São João, Porto, Portugal; Faculty of Medicine, University of Porto, Portugal.
| | - M Drummond
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal; Sleep and Non-Invasive Ventilation Unit, Centro Hospitalar Universitário São João, Porto, Portugal; Faculty of Medicine, University of Porto, Portugal.
| |
Collapse
|
10
|
Mayneris-Perxachs J, Cardellini M, Hoyles L, Latorre J, Davato F, Moreno-Navarrete JM, Arnoriaga-Rodríguez M, Serino M, Abbott J, Barton RH, Puig J, Fernández-Real X, Ricart W, Tomlinson C, Woodbridge M, Gentileschi P, Butcher SA, Holmes E, Nicholson JK, Pérez-Brocal V, Moya A, Clain DM, Burcelin R, Dumas ME, Federici M, Fernández-Real JM. Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome. Microbiome 2021; 9:104. [PMID: 33962692 PMCID: PMC8106161 DOI: 10.1186/s40168-021-01052-7] [Citation(s) in RCA: 58] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Accepted: 03/18/2021] [Indexed: 05/30/2023]
Abstract
BACKGROUND The gut microbiome and iron status are known to play a role in the pathophysiology of non-alcoholic fatty liver disease (NAFLD), although their complex interaction remains unclear. RESULTS Here, we applied an integrative systems medicine approach (faecal metagenomics, plasma and urine metabolomics, hepatic transcriptomics) in 2 well-characterised human cohorts of subjects with obesity (discovery n = 49 and validation n = 628) and an independent cohort formed by both individuals with and without obesity (n = 130), combined with in vitro and animal models. Serum ferritin levels, as a markers of liver iron stores, were positively associated with liver fat accumulation in parallel with lower gut microbial gene richness, composition and functionality. Specifically, ferritin had strong negative associations with the Pasteurellaceae, Leuconostocaceae and Micrococcaea families. It also had consistent negative associations with several Veillonella, Bifidobacterium and Lactobacillus species, but positive associations with Bacteroides and Prevotella spp. Notably, the ferritin-associated bacterial families had a strong correlation with iron-related liver genes. In addition, several bacterial functions related to iron metabolism (transport, chelation, heme and siderophore biosynthesis) and NAFLD (fatty acid and glutathione biosynthesis) were also associated with the host serum ferritin levels. This iron-related microbiome signature was linked to a transcriptomic and metabolomic signature associated to the degree of liver fat accumulation through hepatic glucose metabolism. In particular, we found a consistent association among serum ferritin, Pasteurellaceae and Micrococcacea families, bacterial functions involved in histidine transport, the host circulating histidine levels and the liver expression of GYS2 and SEC24B. Serum ferritin was also related to bacterial glycine transporters, the host glycine serum levels and the liver expression of glycine transporters. The transcriptomic findings were replicated in human primary hepatocytes, where iron supplementation also led to triglycerides accumulation and induced the expression of lipid and iron metabolism genes in synergy with palmitic acid. We further explored the direct impact of the microbiome on iron metabolism and liver fact accumulation through transplantation of faecal microbiota into recipient's mice. In line with the results in humans, transplantation from 'high ferritin donors' resulted in alterations in several genes related to iron metabolism and fatty acid accumulation in recipient's mice. CONCLUSIONS Altogether, a significant interplay among the gut microbiome, iron status and liver fat accumulation is revealed, with potential significance for target therapies. Video abstract.
Collapse
Affiliation(s)
- Jordi Mayneris-Perxachs
- Department of Endocrinology, Diabetes and Nutrition, Hospital of Girona "Dr Josep Trueta", Girona, Spain
- Departament de Ciències Mèdiques, University of Girona, Girona and Biomedical Research Institute of Girona (IdibGi), Girona, Spain
- CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Girona, Spain
| | - Marina Cardellini
- Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy
| | - Lesley Hoyles
- Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK
- Department of Bioscience, School of Science and Technology, Nottingham Trent University, Nottingham, NG11 8NS, UK
| | - Jèssica Latorre
- Department of Endocrinology, Diabetes and Nutrition, Hospital of Girona "Dr Josep Trueta", Girona, Spain
- Departament de Ciències Mèdiques, University of Girona, Girona and Biomedical Research Institute of Girona (IdibGi), Girona, Spain
- CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Girona, Spain
| | - Francesca Davato
- Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy
| | - José Maria Moreno-Navarrete
- Department of Endocrinology, Diabetes and Nutrition, Hospital of Girona "Dr Josep Trueta", Girona, Spain
- Departament de Ciències Mèdiques, University of Girona, Girona and Biomedical Research Institute of Girona (IdibGi), Girona, Spain
- CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Girona, Spain
| | - María Arnoriaga-Rodríguez
- Department of Endocrinology, Diabetes and Nutrition, Hospital of Girona "Dr Josep Trueta", Girona, Spain
- Departament de Ciències Mèdiques, University of Girona, Girona and Biomedical Research Institute of Girona (IdibGi), Girona, Spain
- CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Girona, Spain
| | - Matteo Serino
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Team 2: 'Intestinal Risk Factors, Diabetes, Dyslipidemia, and Heart Failure', 31432, Toulouse Cedex 4, France
| | - James Abbott
- Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK
| | - Richard H Barton
- Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK
| | - Josep Puig
- Department of Endocrinology, Diabetes and Nutrition, Hospital of Girona "Dr Josep Trueta", Girona, Spain
- Departament de Ciències Mèdiques, University of Girona, Girona and Biomedical Research Institute of Girona (IdibGi), Girona, Spain
- CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Girona, Spain
| | | | - Wifredo Ricart
- Department of Endocrinology, Diabetes and Nutrition, Hospital of Girona "Dr Josep Trueta", Girona, Spain
- Departament de Ciències Mèdiques, University of Girona, Girona and Biomedical Research Institute of Girona (IdibGi), Girona, Spain
- CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Girona, Spain
| | - Christopher Tomlinson
- Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK
| | - Mark Woodbridge
- Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK
| | | | - Sarah A Butcher
- Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK
| | - Elaine Holmes
- Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK
| | - Jeremy K Nicholson
- Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK
| | - Vicente Pérez-Brocal
- Unidad Mixta de Investigación en Genómica y Salud, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) and Instituto de Biología Integrativa de Sistemas, Universitat de València and Consejo Superior de Investigaciones Científicas (CSIC), València, Spain
- CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Andrés Moya
- Unidad Mixta de Investigación en Genómica y Salud, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) and Instituto de Biología Integrativa de Sistemas, Universitat de València and Consejo Superior de Investigaciones Científicas (CSIC), València, Spain
- CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Donald Mc Clain
- Department of Internal Medicine, Wake Forest School of Medicine, Winston Salem, NC, 27157, USA
- The W. G. Hefner Veterans Affairs Medical Center, Salisbury, NC, 28144, USA
| | - Rémy Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Team 2: 'Intestinal Risk Factors, Diabetes, Dyslipidemia, and Heart Failure', 31432, Toulouse Cedex 4, France
| | - Marc-Emmanuel Dumas
- Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK
- Section of Genomic and Environmental Medicine, National Heart & Lung Institute, Imperial College London, Dovehouse Street, London, SW3 6LY, UK
- European Genomic Institute for Diabetes, CNRS UMR 8199, INSERM UMR 1283, Institut Pasteur de Lille, Lille University Hospital, University of Lille, 59045, Lille, France
- McGill University and Genome Quebec Innovation Centre, 740 Doctor Penfield Avenue, Montréal, QC, H3A 0G1, Canada
| | - Massimo Federici
- Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy
| | - José-Manuel Fernández-Real
- Department of Endocrinology, Diabetes and Nutrition, Hospital of Girona "Dr Josep Trueta", Girona, Spain.
- Departament de Ciències Mèdiques, University of Girona, Girona and Biomedical Research Institute of Girona (IdibGi), Girona, Spain.
- CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Girona, Spain.
| |
Collapse
|
11
|
Serino M, Freitas C, Saleiro S, Cabrita B, Conde M, Fernandes MGO, Magalhães A. Airway stents in malignant central airway obstruction. Pulmonology 2021; 27:466-469. [PMID: 33744216 DOI: 10.1016/j.pulmoe.2021.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2020] [Revised: 02/08/2021] [Accepted: 02/10/2021] [Indexed: 11/20/2022] Open
Affiliation(s)
- M Serino
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal.
| | - C Freitas
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal; Faculty of Medicine, University of Porto, Portugal
| | - S Saleiro
- Pulmonology Department, Instituto Português de Oncologia do Porto, Porto, Portugal
| | - B Cabrita
- Pulmonology Department, Hospital Pedro Hispano, Matosinhos, Portugal
| | - M Conde
- Pulmonology Department, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal
| | - M G O Fernandes
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal; Faculty of Medicine, University of Porto, Portugal
| | - A Magalhães
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal
| |
Collapse
|
12
|
Bidault-Jourdainne V, Merlen G, Glénisson M, Doignon I, Garcin I, Péan N, Boisgard R, Ursic-Bedoya J, Serino M, Ullmer C, Humbert L, Abdelrafee A, Golse N, Vibert E, Duclos-Vallée JC, Rainteau D, Tordjmann T. TGR5 controls bile acid composition and gallbladder function to protect the liver from bile acid overload. JHEP Rep 2020; 3:100214. [PMID: 33604531 PMCID: PMC7872982 DOI: 10.1016/j.jhepr.2020.100214] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Revised: 10/29/2020] [Accepted: 10/30/2020] [Indexed: 12/13/2022] Open
Abstract
Background & Aims As the composition of the bile acid (BA) pool has a major impact on liver pathophysiology, we studied its regulation by the BA receptor Takeda G protein coupled receptor (TGR5), which promotes hepatoprotection against BA overload. Methods Wild-type, total and hepatocyte-specific TGR5-knockout, and TGR5-overexpressing mice were used in: partial (66%) and 89% extended hepatectomies (EHs) upon normal, ursodeoxycholic acid (UDCA)- or cholestyramine (CT)-enriched diet, bile duct ligation (BDL), cholic acid (CA)-enriched diet, and TGR5 agonist (RO) treatments. We thereby studied the impact of TGR5 on: BA composition, liver injury, regeneration and survival. We also performed analyses on the gut microbiota (GM) and gallbladder (GB). Liver BA composition was analysed in patients undergoing major hepatectomy. Results The TGR5-KO hyperhydrophobic BA composition was not directly related to altered BA synthesis, nor to TGR5-KO GM dysbiosis, as supported by hepatocyte-specific KO mice and co-housing experiments, respectively. The TGR5-dependent control of GB dilatation was crucial for BA composition, as determined by experiments including RO treatment and/or cholecystectomy. The poor TGR5-KO post-EH survival rate, related to exacerbated peribiliary necrosis and BA overload, was improved by shifting BAs toward a less toxic composition (CT treatment). After either BDL or a CA-enriched diet with or without cholecystectomy, we found that GB dilatation had strong TGR5-dependent hepatoprotective properties. In patients, a more hydrophobic liver BA composition was correlated with an unfavourable outcome after hepatectomy. Conclusions BA composition is crucial for hepatoprotection in mice and humans. We indicate TGR5 as a key regulator of BA profile and thereby as a potential hepatoprotective target under BA overload conditions. Lay summary Through multiple in vivo experimental approaches in mice, together with a patient study, this work brings some new light on the relationships between biliary homeostasis, gallbladder function, and liver protection. We showed that hepatic bile acid composition is crucial for optimal liver repair, not only in mice, but also in human patients undergoing major hepatectomy. Reducing BA hydrophobicity improves outcomes after major hepatectomy in mice. The BA receptor TGR5 controls BA pool composition, which is crucial for liver repair. TGR5 targets the gallbladder to induce a hepatoprotective effect. In patients, a more hydrophobic BA pool is associated with liver injury after hepatectomy.
Collapse
Key Words
- ALP, alkaline phosphatase
- ALT, alanine aminotransferase
- BA, bile acid
- BDL, bile duct ligation
- Bile acids
- CA, cholic acid
- CC, cholecystectomy
- CT, cholestyramine
- CYP, cytochrome P450
- EH, extended hepatectomy
- GB, gallbladder
- GM, gut microbiota
- GPBAR1
- GPBAR1, G protein-coupled bile acid receptor 1
- Gallbladder
- HI, hydrophobicity index
- Hepatoprotection
- KO, knockout
- ND, normal diet
- OA, oleanolic acid
- PH, partial hepatectomy
- TBA, total BA
- TGR5
- TGR5, Takeda G protein coupled receptor
- UDCA, ursodeoxycholic acid
- WT, wild-type
Collapse
Affiliation(s)
| | - Grégory Merlen
- Université Paris Saclay, Faculté des Sciences d'Orsay, INSERM U.1193, bât. 443, 91405, Orsay, France
| | - Mathilde Glénisson
- Université Paris Saclay, Faculté des Sciences d'Orsay, INSERM U.1193, bât. 443, 91405, Orsay, France
| | - Isabelle Doignon
- Université Paris Saclay, Faculté des Sciences d'Orsay, INSERM U.1193, bât. 443, 91405, Orsay, France
| | - Isabelle Garcin
- Université Paris Saclay, Faculté des Sciences d'Orsay, INSERM U.1193, bât. 443, 91405, Orsay, France
| | - Noémie Péan
- Université Paris Saclay, Faculté des Sciences d'Orsay, INSERM U.1193, bât. 443, 91405, Orsay, France
| | - Raphael Boisgard
- Plateforme d'Imagerie du Petit Animal, SHFJ, 91405, Orsay, France
| | - José Ursic-Bedoya
- Université Paris Saclay, Faculté des Sciences d'Orsay, INSERM U.1193, bât. 443, 91405, Orsay, France
| | - Matteo Serino
- IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, U1220, CHU Purpan, CS60039, 31024, Toulouse, France
| | | | - Lydie Humbert
- Sorbonne Université, Centre de Recherche Saint Antoine, CRSA, INSERM U 1057, 75571, Paris Cedex 12, France
| | - Ahmed Abdelrafee
- Centre Hépato-Biliaire, Hôpital Paul Brousse, Université Paris-Saclay, 94800, Villejuif, France
| | - Nicolas Golse
- Centre Hépato-Biliaire, Hôpital Paul Brousse, Université Paris-Saclay, 94800, Villejuif, France
| | - Eric Vibert
- Centre Hépato-Biliaire, Hôpital Paul Brousse, Université Paris-Saclay, 94800, Villejuif, France
| | | | - Dominique Rainteau
- Sorbonne Université, Centre de Recherche Saint Antoine, CRSA, INSERM U 1057, 75571, Paris Cedex 12, France
| | - Thierry Tordjmann
- Université Paris Saclay, Faculté des Sciences d'Orsay, INSERM U.1193, bât. 443, 91405, Orsay, France
| |
Collapse
|
13
|
Serino M, van Zeller M, Martins N, Drummond M. Severe asthma intervention in adult obese patients. Pulmonology 2020; 26:325-327. [PMID: 32553823 DOI: 10.1016/j.pulmoe.2020.04.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2019] [Revised: 04/08/2020] [Accepted: 04/09/2020] [Indexed: 10/24/2022] Open
Affiliation(s)
- M Serino
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal.
| | - M van Zeller
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal; Faculty of Medicine, University of Porto, Portugal
| | - N Martins
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal; Faculty of Medicine, University of Porto, Portugal; Institute for Research and Innovation in Health, University of Porto, Portugal
| | - M Drummond
- Pulmonology Department, Centro Hospitalar Universitário São João, Porto, Portugal; Faculty of Medicine, University of Porto, Portugal
| |
Collapse
|
14
|
Abstract
It has recently become evident that the periodontium (gingiva, desmodontal ligament, cementum and alveolar bone) and the associated microbiota play a pivotal role in regulating human health and diseases. The oral cavity is the second largest microbiota in the body with around 500 different bacterial species identified today. When disruption of oral cavity and dysbiosis occur, the proportion of strict anaerobic Gram-negative bacteria is then increased. Patients with periodontitis present 27 to 53% more risk to develop diabetes than the control population suggesting that periodontitis is an aggravating factor in the incidence of diabetes. Moreover, dysbiosis of oral microbiota is involved in both periodontal and metabolic disorders (cardiovascular diseases, dyslipidaemia …). The oral diabetic dysbiosis is characterized by a specific bacteria Porphyromonas, which is highly expressed in periodontal diseases and could exacerbate insulin resistance. In this review, we will address the nature of the oral microbiota and how it affects systemic pathologies with a bidirectional interaction. We also propose that using prebiotics like Akkermansia muciniphila may influence oral microbiota as novel therapeutic strategies. The discovery of the implication of oral microbiota for the control of metabolic diseases could be a new way for personalized medicine.
Collapse
Affiliation(s)
- Matthieu Minty
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432, Toulouse, France
- Université Paul Sabatier III (UPS), F-31432, Toulouse, France
- CHU Toulouse, Service d'Odontologie Toulouse, F-3100, Toulouse, France
| | - Thibault Canceil
- Université Paul Sabatier III (UPS), F-31432, Toulouse, France
- CHU Toulouse, Service d'Odontologie Toulouse, F-3100, Toulouse, France
| | - Matteo Serino
- INSERM, INRA, ENVT, UPS, IRSD, Université de Toulouse, 31024, Toulouse, France
| | - Remy Burcelin
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432, Toulouse, France
- Université Paul Sabatier III (UPS), F-31432, Toulouse, France
- CHU Toulouse, Service d'Odontologie Toulouse, F-3100, Toulouse, France
| | - François Tercé
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432, Toulouse, France
- Université Paul Sabatier III (UPS), F-31432, Toulouse, France
- CHU Toulouse, Service d'Odontologie Toulouse, F-3100, Toulouse, France
| | - Vincent Blasco-Baque
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432, Toulouse, France.
- Université Paul Sabatier III (UPS), F-31432, Toulouse, France.
- CHU Toulouse, Service d'Odontologie Toulouse, F-3100, Toulouse, France.
- INSERM UMR1048-I2MC Team 2 « Intestinal Risk Factors, Diabetes and Dyslipidemia » Building L4, 1st floor, Hospital of Rangueil 1, Avenue Jean Poulhès, 84225 31432, Toulouse Cedex 4 Lab, BP, France.
| |
Collapse
|
15
|
Brochot A, Azalbert V, Landrier J, Tourniaire F, Serino M. Front Cover: A Two‐Week Treatment with Plant Extracts Changes Gut Microbiota, Caecum Metabolome, and Markers of Lipid Metabolism in ob/ob Mice. Mol Nutr Food Res 2019. [DOI: 10.1002/mnfr.201970043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
16
|
Brochot A, Azalbert V, Landrier J, Tourniaire F, Serino M. A Two-Week Treatment with Plant Extracts Changes Gut Microbiota, Caecum Metabolome, and Markers of Lipid Metabolism in ob/ob Mice. Mol Nutr Food Res 2019; 63:e1900403. [PMID: 31206248 PMCID: PMC6771983 DOI: 10.1002/mnfr.201900403] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2019] [Revised: 06/04/2019] [Indexed: 12/25/2022]
Abstract
SCOPE Targeting gut microbiota dysbiosis by prebiotics is effective, though side effects such as abdominal bloating and flatulence may arise following high prebiotic consumption over weeks. The aim is therefore to optimize the current protocol for prebiotic use. METHODS AND RESULTS To examine the prebiotic properties of plant extracts, two independent studies are conducted in ob/ob mice, over two weeks. In the first study, Porphyra umbilicalis and Melissa officinalis L. extracts are evaluated; in the second study, a high vs low dose of an Emblica officinalis Gaertn extract is assessed. These plant extracts affect gut microbiota, caecum metabolome, and induce a significant lower plasma triacylglycerols (TG) following treatment with P. umbilicalis and significantly higher plasma free fatty acids (FFA) following treatment with the low-dose of E. officinalis Gaertn. Glucose- and insulin-tolerance are not affected but white adipose tissue and liver gene expression are modified. In the first study, IL-6 hepatic gene expression is significantly (adjusted p = 0.0015) and positively (r = 0.80) correlated with the bacterial order Clostridiales in all mice. CONCLUSION The data show that a two-week treatment with plant extracts affects the dysbiotic gut microbiota and changes both caecum metabolome and markers of lipid metabolism in ob/ob mice.
Collapse
Affiliation(s)
| | - Vincent Azalbert
- Institut National de la Santé et de la Recherche Médicale (INSERM)ToulouseFrance
- Unité Mixte de Recherche (UMR) 1048Institut de Maladies Métaboliques et Cardiovasculaires (I2MC)Université Paul Sabatier (UPS)Toulouse31432France
| | - Jean‐François Landrier
- Centre de recherche CardioVasculaire et Nutrition (C2VN)Aix‐Marseille Université, INRA, INSERMMarseille13385France
- CriBioMCriblage Biologique MarseilleFaculté de Médecine de la TimoneMarseilleFrance
| | - Franck Tourniaire
- Centre de recherche CardioVasculaire et Nutrition (C2VN)Aix‐Marseille Université, INRA, INSERMMarseille13385France
- CriBioMCriblage Biologique MarseilleFaculté de Médecine de la TimoneMarseilleFrance
| | - Matteo Serino
- IRSDUniversité de Toulouse, INSERM, INRA, ENVT, UPSToulouse31024France
| |
Collapse
|
17
|
Affiliation(s)
- Matteo Serino
- IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France.
| |
Collapse
|
18
|
Zhang-Sun W, Tercé F, Burcelin R, Novikov A, Serino M, Caroff M. Structure function relationships in three lipids A from the Ralstonia genus rising in obese patients. Biochimie 2019; 159:72-80. [PMID: 30703476 DOI: 10.1016/j.biochi.2019.01.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Accepted: 01/22/2019] [Indexed: 10/27/2022]
Abstract
The identification of a functional molecular moiety relating the lipopolysaccharides (LPSs) to their capacity to induce inflammation-mediated metabolic diseases needed to be performed. We previously described a proportional increase in the relative abundance of the 16 SrDNA bacterial gene from the genus Ralstonia, within the microbiota from the adipose tissue stroma vascular fraction of obese patients, suggesting a causal role of the bacteria. Therefore, we first characterized the structures of the lipids A, the inflammatory inducing moieties of LPSs, of three Ralstonia species: Ralstonia eutropha, R. mannitolilytica and R. pickettii, and then compared each, in terms of in vitro inflammatory capacities. R. pickettii lipid A displaying only 5 Fatty Acids (FA) was a weaker inducer of inflammation, compared to the two other species harboring hexa-acylated lipids A, despite the presence of 2 AraN substituents on the phosphate groups. With regard to in vitro pro-inflammatory activities, TNF-α and IL-6 inducing capacities were compared on THP-1 cells treated with LPSs isolated from the three Ralstonia. R. pickettii, with low inflammatory capacities, and recently involved in nosocomial outcomes, could explain the low inflammatory level reported in previous studies on diabetic patients and animals. In addition, transmission electron microscopy was performed on the three Ralstonia species. It showed that the R. pickettii under-acylated LPSs, with a higher level of phosphate substitution had the capacity of producing more outer membrane vesicles (OMVs). The latter could facilitate transfer of LPSs to the blood and explain the increased low-grade inflammation observed in obese/diabetic patients.
Collapse
Affiliation(s)
- Wei Zhang-Sun
- I2BC, Centre National de la Recherche Scientifique, Université de Paris-Sud, Université de Paris-Saclay, Orsay, France
| | - François Tercé
- Université de Toulouse, UPS, Institut des Maladies Métaboliques et Cardiovasculaires de Rangueil I(2)MC, INSERM, Toulouse, France
| | - Remy Burcelin
- Université de Toulouse, UPS, Institut des Maladies Métaboliques et Cardiovasculaires de Rangueil I(2)MC, INSERM, Toulouse, France
| | - Alexey Novikov
- LPS-BioSciences, I2BC, Bâtiment 409, Université de Paris-Sud, Orsay, France
| | - Matteo Serino
- Université de Toulouse, UPS, Institut des Maladies Métaboliques et Cardiovasculaires de Rangueil I(2)MC, INSERM, Toulouse, France
| | - Martine Caroff
- I2BC, Centre National de la Recherche Scientifique, Université de Paris-Sud, Université de Paris-Saclay, Orsay, France; LPS-BioSciences, I2BC, Bâtiment 409, Université de Paris-Sud, Orsay, France.
| |
Collapse
|
19
|
Minty M, Canceill T, Lê S, Dubois P, Amestoy O, Loubieres P, Christensen JE, Champion C, Azalbert V, Grasset E, Hardy S, Loubes JM, Mallet JP, Tercé F, Vergnes JN, Burcelin R, Serino M, Diemer F, Blasco-Baque V. Oral health and microbiota status in professional rugby players: A case-control study. J Dent 2018; 79:53-60. [PMID: 30292825 DOI: 10.1016/j.jdent.2018.10.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2018] [Revised: 09/29/2018] [Accepted: 10/03/2018] [Indexed: 12/20/2022] Open
Abstract
OBJECTIVE Elite athletes are prone to develop oral diseases, which could increase the risk for injuries. The aim of this study was to evaluate the oral health and the composition of oral microbiota of elite rugby players compared to the general population. METHODS We set up a case-control study by screening 24 professional rugby players (PRG) and 22 control patients (CG) for dental and gingival examinations and performed a taxonomic analysis and a predicted functional analysis of oral microbiota. RESULTS The Decay, Missing and Filled (DMF) teeth index (5.54 ± 6.18 versus 2.14 ± 3.01; p = 0.01) and the frequency of gingivitis (58,33% versus 13.63%) were significantly increased in PRG compared to CG. PRG were characterized by a dysbiotic oral microbiota (Shannon Index: 3.32 ± 0.62 in PRG versus 3.79 ± 0.68 in CG; p = 0.03) with an increase of Streptococcus (58.43 ± 16.84 versus 42.60 ± 17.45; p = 0.005), the main genus implicated in caries. Predicted metagenomics of oral microbiota in rugby players was suggestive of a cariogenic metagenome favourable to the development of caries. CONCLUSIONS Our study shows that the oral health of PRG was poorer than the general population. PRG are characterized by a dysbiotic oral microbiota with an increase of the relative abundance of Streptococcus genus, positively correlated to the weight and negatively correlated to the diversity of oral microbiota. CLINICAL SIGNIFICANCE Dental screening should be included in the medical follow-up of professional rugby players as a part of their health management. New strategies such as using probiotics like Lactobacillus could help to control the dysbiosis of oral microbiota.
Collapse
Affiliation(s)
- Matthieu Minty
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432 Toulouse, France; Université Paul Sabatier III (UPS), F-31432 Toulouse, France; CHU Toulouse, Service d'Odontologie Toulouse, F-3100, France
| | - Thibault Canceill
- Université Paul Sabatier III (UPS), F-31432 Toulouse, France; CHU Toulouse, Service d'Odontologie Toulouse, F-3100, France
| | - Sylvie Lê
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432 Toulouse, France; Université Paul Sabatier III (UPS), F-31432 Toulouse, France; CHU Toulouse, Service d'Odontologie Toulouse, F-3100, France
| | - Pauline Dubois
- Université Paul Sabatier III (UPS), F-31432 Toulouse, France; CHU Toulouse, Service d'Odontologie Toulouse, F-3100, France
| | - Oihana Amestoy
- Université Paul Sabatier III (UPS), F-31432 Toulouse, France; CHU Toulouse, Service d'Odontologie Toulouse, F-3100, France
| | - Pascale Loubieres
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432 Toulouse, France; Université Paul Sabatier III (UPS), F-31432 Toulouse, France; CHU Toulouse, Service d'Odontologie Toulouse, F-3100, France
| | - Jeffrey E Christensen
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432 Toulouse, France; Université Paul Sabatier III (UPS), F-31432 Toulouse, France
| | - Camille Champion
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432 Toulouse, France; Université Paul Sabatier III (UPS), F-31432 Toulouse, France; Institut de Mathématiques de Toulouse, Université de Toulouse, 118, route de Narbonne, F-31062 Toulouse Cedex 9, France
| | - Vincent Azalbert
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432 Toulouse, France; Université Paul Sabatier III (UPS), F-31432 Toulouse, France
| | - Estelle Grasset
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432 Toulouse, France; Université Paul Sabatier III (UPS), F-31432 Toulouse, France
| | - Sara Hardy
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432 Toulouse, France; Université Paul Sabatier III (UPS), F-31432 Toulouse, France
| | - Jean-Michel Loubes
- Institut de Mathématiques de Toulouse, Université de Toulouse, 118, route de Narbonne, F-31062 Toulouse Cedex 9, France
| | - Jean-Philippe Mallet
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432 Toulouse, France; Université Paul Sabatier III (UPS), F-31432 Toulouse, France
| | - François Tercé
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432 Toulouse, France; Université Paul Sabatier III (UPS), F-31432 Toulouse, France
| | - Jean-Noël Vergnes
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432 Toulouse, France; Université Paul Sabatier III (UPS), F-31432 Toulouse, France; CHU Toulouse, Service d'Odontologie Toulouse, F-3100, France
| | - Rémy Burcelin
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432 Toulouse, France; Université Paul Sabatier III (UPS), F-31432 Toulouse, France
| | - Matteo Serino
- IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France
| | - Franck Diemer
- Université Paul Sabatier III (UPS), F-31432 Toulouse, France; CHU Toulouse, Service d'Odontologie Toulouse, F-3100, France; Clément Ader Institute, UMR-CNRS 5312, Toulouse, France
| | - Vincent Blasco-Baque
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432 Toulouse, France; Université Paul Sabatier III (UPS), F-31432 Toulouse, France; CHU Toulouse, Service d'Odontologie Toulouse, F-3100, France.
| |
Collapse
|
20
|
Hoyles L, Fernández-Real JM, Federici M, Serino M, Abbott J, Charpentier J, Heymes C, Luque JL, Anthony E, Barton RH, Chilloux J, Myridakis A, Martinez-Gili L, Moreno-Navarrete JM, Benhamed F, Azalbert V, Blasco-Baque V, Puig J, Xifra G, Ricart W, Tomlinson C, Woodbridge M, Cardellini M, Davato F, Cardolini I, Porzio O, Gentileschi P, Lopez F, Foufelle F, Butcher SA, Holmes E, Nicholson JK, Postic C, Burcelin R, Dumas ME. Publisher Correction: Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med 2018; 24:1628. [DOI: 10.1038/s41591-018-0169-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
21
|
Hentschinski M, Kusina A, Kutak K, Serino M. TMD splitting functions in [Formula: see text] factorization: the real contribution to the gluon-to-gluon splitting. Eur Phys J C Part Fields 2018; 78:174. [PMID: 29527125 PMCID: PMC5834604 DOI: 10.1140/epjc/s10052-018-5634-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Accepted: 02/10/2018] [Indexed: 12/30/2023]
Abstract
We calculate the transverse momentum dependent gluon-to-gluon splitting function within [Formula: see text]-factorization, generalizing the framework employed in the calculation of the quark splitting functions in Hautmann et al. (Nucl Phys B 865:54-66, arXiv:1205.1759, 2012), Gituliar et al. (JHEP 01:181, arXiv:1511.08439, 2016), Hentschinski et al. (Phys Rev D 94(11):114013, arXiv:1607.01507, 2016) and demonstrate at the same time the consistency of the extended formalism with previous results. While existing versions of [Formula: see text] factorized evolution equations contain already a gluon-to-gluon splitting function i.e. the leading order Balitsky-Fadin-Kuraev-Lipatov (BFKL) kernel or the Ciafaloni-Catani-Fiorani-Marchesini (CCFM) kernel, the obtained splitting function has the important property that it reduces both to the leading order BFKL kernel in the high energy limit, to the Dokshitzer-Gribov-Lipatov-Altarelli-Parisi (DGLAP) gluon-to-gluon splitting function in the collinear limit as well as to the CCFM kernel in the soft limit. At the same time we demonstrate that this splitting kernel can be obtained from a direct calculation of the QCD Feynman diagrams, based on a combined implementation of the Curci-Furmanski-Petronzio formalism for the calculation of the collinear splitting functions and the framework of high energy factorization.
Collapse
Affiliation(s)
- M. Hentschinski
- Departamento de Actuaria, Física y Matemáticas, Universidad de las Americas Puebla, Santa Catarina Martir, 72820 Puebla, Mexico
| | - A. Kusina
- The H. Niewodniczański Institute of Nuclear Physics, Polish Academy of Sciences, ul. Radzikowskiego 152, 31-342 Cracow, Poland
| | - K. Kutak
- The H. Niewodniczański Institute of Nuclear Physics, Polish Academy of Sciences, ul. Radzikowskiego 152, 31-342 Cracow, Poland
| | - M. Serino
- The H. Niewodniczański Institute of Nuclear Physics, Polish Academy of Sciences, ul. Radzikowskiego 152, 31-342 Cracow, Poland
- Department of Physics, Ben Gurion University of the Negev, 8410501 Beer Sheva, Israel
| |
Collapse
|
22
|
Moreno-Navarrete JM, Serino M, Blasco-Baque V, Azalbert V, Barton RH, Cardellini M, Latorre J, Ortega F, Sabater-Masdeu M, Burcelin R, Dumas ME, Ricart W, Federici M, Fernández-Real JM. Gut Microbiota Interacts with Markers of Adipose Tissue Browning, Insulin Action and Plasma Acetate in Morbid Obesity. Mol Nutr Food Res 2018; 62. [PMID: 29105287 DOI: 10.1002/mnfr.201700721] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Revised: 10/09/2017] [Indexed: 12/16/2022]
Abstract
SCOPE To examine the potential relationship among gene expression markers of adipose tissue browning, gut microbiota, and insulin sensitivity in humans. METHODS AND RESULTS Gut microbiota composition and gene markers of browning are analyzed in subcutaneous (SAT) and visceral (VAT) adipose tissue from morbidly obese subjects (n = 34). Plasma acetate is measured through 1 H NMR and insulin sensitivity using euglycemic hyperinsulinemic clamp. Subjects with insulin resistance show an increase in the relative abundance (RA) of the phyla Bacteroidetes and Proteobacteria while RA of Firmicutes is decreased. In all subjects, Firmicutes RA is negatively correlated with HbA1c and fasting triglycerides, whereas Proteobacteria RA was negatively correlated with insulin sensitivity. Firmicutes RA is positively associated with markers of brown adipocytes (PRDM16, UCP1, and DIO2) in SAT, but not in VAT. Multivariate regression analysis indicates that Firmicutes RA contributes significantly to SAT PRDM16, UCP1, and DIO2 mRNA variance after controlling for age, BMI, HbA1c , or insulin sensitivity. Interestingly, Firmicutes RA, specifically those bacteria belonging to the Ruminococcaceae family, is positively associated with plasma acetate levels, which are also linked to SAT PRDM16 mRNA and insulin sensitivity. CONCLUSION Gut microbiota composition is linked to adipose tissue browning and insulin action in morbidly obese subjects, possibly through circulating acetate.
Collapse
Affiliation(s)
- José María Moreno-Navarrete
- Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), Girona, Spain
- Department of Medicine, Universitat de Girona, Girona, Spain
| | - Matteo Serino
- Institut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France
| | - Vincent Blasco-Baque
- Institut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France
| | - Vincent Azalbert
- Institut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France
| | - Richard H Barton
- Faculty of Medicine, Department of Surgery and Cancer, Division of Computational and Systems Medicine, Imperial College London, South Kensington, London, UK
| | - Marina Cardellini
- Department of Systems Medicine and Center for Atherosclerosis, University of Rome "Tor Vergata", Rome, Italy
| | - Jèssica Latorre
- Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), Girona, Spain
| | - Francisco Ortega
- Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), Girona, Spain
| | - Mònica Sabater-Masdeu
- Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), Girona, Spain
| | - Rémy Burcelin
- Institut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France
| | - Marc-Emmanuel Dumas
- Faculty of Medicine, Department of Surgery and Cancer, Division of Computational and Systems Medicine, Imperial College London, South Kensington, London, UK
| | - Wifredo Ricart
- Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), Girona, Spain
- Department of Medicine, Universitat de Girona, Girona, Spain
| | - Massimo Federici
- Department of Systems Medicine and Center for Atherosclerosis, University of Rome "Tor Vergata", Rome, Italy
| | - José Manuel Fernández-Real
- Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), Girona, Spain
- Department of Medicine, Universitat de Girona, Girona, Spain
| |
Collapse
|
23
|
Serino M. Molecular Paths Linking Metabolic Diseases, Gut Microbiota Dysbiosis and Enterobacteria Infections. J Mol Biol 2018; 430:581-590. [PMID: 29374557 DOI: 10.1016/j.jmb.2018.01.010] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2017] [Accepted: 01/19/2018] [Indexed: 02/07/2023]
Abstract
Alterations of both ecology and functions of gut microbiota are conspicuous traits of several inflammatory pathologies, notably metabolic diseases such as obesity and type 2 diabetes. Moreover, the proliferation of enterobacteria, subdominant members of the intestinal microbial ecosystem, has been shown to be favored by Western diet, the strongest inducer of both metabolic diseases and gut microbiota dysbiosis. The inner interdependence between the host and the gut microbiota is based on a plethora of molecular mechanisms by which host and intestinal microbes modify each other. Among these mechanisms are as follows: (i) the well-known metabolic impact of short chain fatty acids, produced by microbial fermentation of complex carbohydrates from plants; (ii) a mutual modulation of miRNAs expression, both on the eukaryotic (host) and prokaryotic (gut microbes) side; (iii) the production by enterobacteria of virulence factors such as the genotoxin colibactin, shown to alter the integrity of host genome and induce a senescence-like phenotype in vitro; (iv) the microbial excretion of outer-membrane vesicles, which, in addition to other functions, may act as a carrier for multiple molecules such as toxins to be delivered to target cells. In this review, I describe the major molecular mechanisms by which gut microbes exert their metabolic impact at a multi-organ level (the gut barrier being in the front line) and support the emerging triad of metabolic diseases, gut microbiota dysbiosis and enterobacteria infections.
Collapse
Affiliation(s)
- Matteo Serino
- IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France.
| |
Collapse
|
24
|
Serino M, Nicolas S, Trabelsi MS, Burcelin R, Blasco-Baque V. Young microbes for adult obesity. Pediatr Obes 2017; 12:e28-e32. [PMID: 27135640 DOI: 10.1111/ijpo.12146] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/24/2015] [Revised: 03/23/2016] [Accepted: 03/25/2016] [Indexed: 12/20/2022]
Abstract
Gut microbes are active participants of host metabolism. At birth, child physiology is committed towards healthiness or sickness depending, in part, on maternal condition (i.e. lean vs obesity) and delivery. Finally, changes from breastfeeding to solid food also account to define gut microbiota ecology in adulthood. Nowadays, alterations of gut microbiota, named dysbiosis, are acquired risk factors for multiple diseases, especially type 2 diabetes and obesity. Despite important evidence linking nutrition to dysbiosis to energetic dysmetabolism, molecular mechanisms for causality are still missing. That the status of gut microbiota of mother and child is crucial for future diseases is witnessed by adulthood overweight and obesity observed in children with dysbiosis. In this short review we highlight the importance of early life events related to the microbiota and their impact on future adult disease risk. Therefore, our effort to treat or prevent metabolic diseases should be addressed towards early or previous life steps, when microbial decisions are going to affect our metabolic fate.
Collapse
Affiliation(s)
- M Serino
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
| | - S Nicolas
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
| | - M-S Trabelsi
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
| | - R Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
| | - V Blasco-Baque
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France.,L.U. 51 « Parodontites et Maladies Générales », Université Paul Sabatier, Faculté de Chirurgie Dentaire, Toulouse, France
| |
Collapse
|
25
|
Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M, Xifra G, Mercader JM, Torrents D, Burcelin R, Ricart W, Perkins R, Fernàndez-Real JM, Bäckhed F. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 2017; 23:850-858. [PMID: 28530702 DOI: 10.1038/nm.4345`1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2016] [Accepted: 04/19/2017] [Indexed: 05/20/2023]
Abstract
Metformin is widely used in the treatment of type 2 diabetes (T2D), but its mechanism of action is poorly defined. Recent evidence implicates the gut microbiota as a site of metformin action. In a double-blind study, we randomized individuals with treatment-naive T2D to placebo or metformin for 4 months and showed that metformin had strong effects on the gut microbiome. These results were verified in a subset of the placebo group that switched to metformin 6 months after the start of the trial. Transfer of fecal samples (obtained before and 4 months after treatment) from metformin-treated donors to germ-free mice showed that glucose tolerance was improved in mice that received metformin-altered microbiota. By directly investigating metformin-microbiota interactions in a gut simulator, we showed that metformin affected pathways with common biological functions in species from two different phyla, and many of the metformin-regulated genes in these species encoded metalloproteins or metal transporters. Our findings provide support for the notion that altered gut microbiota mediates some of metformin's antidiabetic effects.
Collapse
Affiliation(s)
- Hao Wu
- Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - Eduardo Esteve
- Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona, Hospital Josep Trueta, Girona, Spain
- Departament de Medicina, Facultat de Medicina, University of Girona, Girona, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Valentina Tremaroli
- Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - Muhammad Tanweer Khan
- Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - Robert Caesar
- Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - Louise Mannerås-Holm
- Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - Marcus Ståhlman
- Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - Lisa M Olsson
- Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - Matteo Serino
- IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France
| | - Mercè Planas-Fèlix
- Barcelona Supercomputing Center (BSC), Joint BSC-CRG-IRB Research Program in Computational Biology, Barcelona, Spain
| | - Gemma Xifra
- Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona, Hospital Josep Trueta, Girona, Spain
- Departament de Medicina, Facultat de Medicina, University of Girona, Girona, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Josep M Mercader
- Barcelona Supercomputing Center (BSC), Joint BSC-CRG-IRB Research Program in Computational Biology, Barcelona, Spain
| | - David Torrents
- Barcelona Supercomputing Center (BSC), Joint BSC-CRG-IRB Research Program in Computational Biology, Barcelona, Spain
- Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - Rémy Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Université Paul Sabatier (UPS), Unité Mixte de Recherche 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France
| | - Wifredo Ricart
- Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona, Hospital Josep Trueta, Girona, Spain
- Departament de Medicina, Facultat de Medicina, University of Girona, Girona, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Rosie Perkins
- Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - José Manuel Fernàndez-Real
- Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona, Hospital Josep Trueta, Girona, Spain
- Departament de Medicina, Facultat de Medicina, University of Girona, Girona, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Fredrik Bäckhed
- Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
- Sahlgrenska University Hospital, Gothenburg, Sweden
- Novo Nordisk Foundation Center for Basic Metabolic Research, Section for Metabolic Receptology and Enteroendocrinology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
26
|
Blasco-Baque V, Garidou L, Pomié C, Escoula Q, Loubieres P, Le Gall-David S, Lemaitre M, Nicolas S, Klopp P, Waget A, Azalbert V, Colom A, Bonnaure-Mallet M, Kemoun P, Serino M, Burcelin R. Periodontitis induced by Porphyromonas gingivalis drives periodontal microbiota dysbiosis and insulin resistance via an impaired adaptive immune response. Gut 2017; 66:872-885. [PMID: 26838600 PMCID: PMC5531227 DOI: 10.1136/gutjnl-2015-309897] [Citation(s) in RCA: 181] [Impact Index Per Article: 25.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/04/2015] [Accepted: 12/18/2015] [Indexed: 01/11/2023]
Abstract
OBJECTIVE To identify a causal mechanism responsible for the enhancement of insulin resistance and hyperglycaemia following periodontitis in mice fed a fat-enriched diet. DESIGN We set-up a unique animal model of periodontitis in C57Bl/6 female mice by infecting the periodontal tissue with specific and alive pathogens like Porphyromonas gingivalis (Pg), Fusobacterium nucleatum and Prevotella intermedia. The mice were then fed with a diabetogenic/non-obesogenic fat-enriched diet for up to 3 months. Alveolar bone loss, periodontal microbiota dysbiosis and features of glucose metabolism were quantified. Eventually, adoptive transfer of cervical (regional) and systemic immune cells was performed to demonstrate the causal role of the cervical immune system. RESULTS Periodontitis induced a periodontal microbiota dysbiosis without mainly affecting gut microbiota. The disease concomitantly impacted on the regional and systemic immune response impairing glucose metabolism. The transfer of cervical lymph-node cells from infected mice to naive recipients guarded against periodontitis-aggravated metabolic disease. A treatment with inactivated Pg prior to the periodontal infection induced specific antibodies against Pg and protected the mouse from periodontitis-induced dysmetabolism. Finally, a 1-month subcutaneous chronic infusion of low rates of lipopolysaccharides from Pg mimicked the impact of periodontitis on immune and metabolic parameters. CONCLUSIONS We identified that insulin resistance in the high-fat fed mouse is enhanced by pathogen-induced periodontitis. This is caused by an adaptive immune response specifically directed against pathogens and associated with a periodontal dysbiosis.
Collapse
Affiliation(s)
- Vincent Blasco-Baque
- INSERM U1048, Toulouse, France,Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France,Université Paul Sabatier (UPS), Toulouse, France,Faculté de Chirurgie-Dentaire de Toulouse, Technical platform of Research in Odontology, Toulouse Cedex 09, France
| | - Lucile Garidou
- INSERM U1048, Toulouse, France,Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France,Université Paul Sabatier (UPS), Toulouse, France
| | - Céline Pomié
- INSERM U1048, Toulouse, France,Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France,Université Paul Sabatier (UPS), Toulouse, France
| | - Quentin Escoula
- INSERM U1048, Toulouse, France,Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France,Université Paul Sabatier (UPS), Toulouse, France
| | - Pascale Loubieres
- INSERM U1048, Toulouse, France,Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France,Université Paul Sabatier (UPS), Toulouse, France,Faculté de Chirurgie-Dentaire de Toulouse, Technical platform of Research in Odontology, Toulouse Cedex 09, France
| | | | - Mathieu Lemaitre
- Faculté de Chirurgie-Dentaire de Toulouse, Technical platform of Research in Odontology, Toulouse Cedex 09, France
| | - Simon Nicolas
- INSERM U1048, Toulouse, France,Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France,Université Paul Sabatier (UPS), Toulouse, France
| | - Pascale Klopp
- INSERM U1048, Toulouse, France,Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France,Université Paul Sabatier (UPS), Toulouse, France
| | - Aurélie Waget
- INSERM U1048, Toulouse, France,Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France,Université Paul Sabatier (UPS), Toulouse, France
| | - Vincent Azalbert
- INSERM U1048, Toulouse, France,Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France,Université Paul Sabatier (UPS), Toulouse, France
| | - André Colom
- INSERM U1048, Toulouse, France,Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France,Université Paul Sabatier (UPS), Toulouse, France
| | | | - Philippe Kemoun
- Faculté de Chirurgie-Dentaire de Toulouse, Technical platform of Research in Odontology, Toulouse Cedex 09, France
| | - Matteo Serino
- INSERM U1048, Toulouse, France,Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France,Université Paul Sabatier (UPS), Toulouse, France
| | - Rémy Burcelin
- INSERM U1048, Toulouse, France,Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France,Université Paul Sabatier (UPS), Toulouse, France
| |
Collapse
|
27
|
Blasco-Baque V, Coupé B, Fabre A, Handgraaf S, Gourdy P, Arnal JF, Courtney M, Schuster-Klein C, Guardiola B, Tercé F, Burcelin R, Serino M. Associations between hepatic miRNA expression, liver triacylglycerols and gut microbiota during metabolic adaptation to high-fat diet in mice. Diabetologia 2017; 60:690-700. [PMID: 28105518 PMCID: PMC6518927 DOI: 10.1007/s00125-017-4209-3] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Accepted: 12/14/2016] [Indexed: 01/30/2023]
Abstract
AIMS/HYPOTHESIS Despite the current pandemic of metabolic diseases, our understanding of the diverse nature of the development of metabolic alterations in people who eat a high-fat diet (HFD) is still poor. We recently demonstrated a cardio-metabolic adaptation in mice fed an HFD, which was characterised by a specific gut and periodontal microbiota profile. Since the severity of hepatic disease is characterised by specific microRNA (miRNA) signatures and the gut microbiota is a key driver of both hepatic disease and miRNA expression, we analysed the expression of three hepatic miRNA and studied their correlation with hepatic triacylglycerol content and gut microbiota. METHODS Two cohorts of C57BL/6 4-week-old wild-type (WT) male mice (n = 62 and n = 96) were fed an HFD for 3 months to provide a model of metabolic adaptation. Additionally 8-week-old C57BL/6 mice, either WT or of different genotypes, with diverse gut microbiota (ob/ob, Nod1, Cd14 knockout [Cd14KO] and Nod2) or without gut microbiota (axenic mice) were fed a normal chow diet. Following which, glycaemic index, body weight, blood glucose levels and hepatic triacylglycerol levels were measured. Gut (caecum) microbiota taxa were analysed by pyrosequencing. To analyse hepatic miRNA expression, real-time PCR was performed on total extracted miRNA samples. Data were analysed using two-way ANOVA followed by the Dunnett's post hoc test, or by the unpaired Student's t test. A cluster analysis and multivariate analyses were also performed. RESULTS Our results demonstrated that the expression of miR-181a, miR-666 and miR-21 in primary murine hepatocytes is controlled by lipopolysaccharide in a dose-dependent manner. Of the gut microbiota, Firmicutes were positively correlated and Proteobacteria and Bacteroides acidifaciens were negatively correlated with liver triacylglycerol levels. Furthermore, the relative abundance of Firmicutes was negatively correlated with hepatic expression of miR-666 and miR-21. In contrast, the relative abundance of B. acidifaciens was positively correlated with miR-21. CONCLUSIONS/INTERPRETATION We propose the involvement of hepatic miRNA, liver triacylglycerols and gut microbiota as a new triad that underlies the molecular mechanisms by which gut microbiota governs hepatic pathophysiology during metabolic adaptation to HFD.
Collapse
Affiliation(s)
- Vincent Blasco-Baque
- Institut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France
- Unité Mixte de Recherche, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse, France
- Faculté de Chirurgie Dentaire de Toulouse, Université Paul Sabatier, Toulouse, France
| | | | - Aurelie Fabre
- Institut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France
- Unité Mixte de Recherche, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse, France
| | - Sandra Handgraaf
- Institut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France
- Unité Mixte de Recherche, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse, France
| | - Pierre Gourdy
- Institut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France
- Unité Mixte de Recherche, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse, France
| | - Jean-François Arnal
- Institut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France
- Unité Mixte de Recherche, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse, France
| | | | - Carole Schuster-Klein
- Pôle d'Innovation Thérapeutique Métabolisme, Recherche de Découvertes, Institut de Recherches Servier, Suresnes, France
| | - Beatrice Guardiola
- Pôle d'Innovation Thérapeutique Métabolisme, Recherche de Découvertes, Institut de Recherches Servier, Suresnes, France
| | - François Tercé
- Institut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France
- Unité Mixte de Recherche, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse, France
| | - Rémy Burcelin
- Institut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France
- Unité Mixte de Recherche, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse, France
| | - Matteo Serino
- Institut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France.
- Unité Mixte de Recherche, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse, France.
- Unité Mixte de Recherche (UMR) 1220, Institut de Recherche en Santé Digestive (IRSD), Université Paul Sabatier (UPS), Centre Hospitalier Universitaire (CHU) Purpan, Place du Docteur Baylac, CS 60039, 31024, Toulouse, Cedex 3, France.
| |
Collapse
|
28
|
Nicolas S, Blasco-Baque V, Fournel A, Gilleron J, Klopp P, Waget A, Ceppo F, Marlin A, Padmanabhan R, Iacovoni JS, Tercé F, Cani PD, Tanti JF, Burcelin R, Knauf C, Cormont M, Serino M. Transfer of dysbiotic gut microbiota has beneficial effects on host liver metabolism. Mol Syst Biol 2017; 13:921. [PMID: 28302863 PMCID: PMC5371731 DOI: 10.15252/msb.20167356] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Gut microbiota dysbiosis has been implicated in a variety of systemic disorders, notably metabolic diseases including obesity and impaired liver function, but the underlying mechanisms are uncertain. To investigate this question, we transferred caecal microbiota from either obese or lean mice to antibiotic-free, conventional wild-type mice. We found that transferring obese-mouse gut microbiota to mice on normal chow (NC) acutely reduces markers of hepatic gluconeogenesis with decreased hepatic PEPCK activity, compared to non-inoculated mice, a phenotypic trait blunted in conventional NOD2 KO mice. Furthermore, transferring of obese-mouse microbiota changes both the gut microbiota and the microbiome of recipient mice. We also found that transferring obese gut microbiota to NC-fed mice then fed with a high-fat diet (HFD) acutely impacts hepatic metabolism and prevents HFD-increased hepatic gluconeogenesis compared to non-inoculated mice. Moreover, the recipient mice exhibit reduced hepatic PEPCK and G6Pase activity, fed glycaemia and adiposity. Conversely, transfer of lean-mouse microbiota does not affect markers of hepatic gluconeogenesis. Our findings provide a new perspective on gut microbiota dysbiosis, potentially useful to better understand the aetiology of metabolic diseases.
Collapse
Affiliation(s)
- Simon Nicolas
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France
| | - Vincent Blasco-Baque
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France.,Faculté de Chirurgie Dentaire de Toulouse, Université Paul Sabatier, Toulouse Cedex, France
| | - Audren Fournel
- Toulouse III, Institut de Recherche en Santé Digestive (IRSD) Team 3, "Intestinal Neuroimmune Interactions" INSERM U1220, Université Paul Sabatier, Toulouse Cedex 3, France.,European Associated Laboratory NeuroMicrobiota (INSERM/UCL), Bâtiment B - Pavillon Lefebvre, Toulouse Cedex 3, France
| | - Jerome Gilleron
- INSERM Unité 1065/Centre Méditerranéen de Médecine Moléculaire (C3M), Université Côte d'Azur, Nice, France
| | - Pascale Klopp
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France
| | - Aurelie Waget
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France
| | - Franck Ceppo
- INSERM Unité 1065/Centre Méditerranéen de Médecine Moléculaire (C3M), Université Côte d'Azur, Nice, France
| | - Alysson Marlin
- Toulouse III, Institut de Recherche en Santé Digestive (IRSD) Team 3, "Intestinal Neuroimmune Interactions" INSERM U1220, Université Paul Sabatier, Toulouse Cedex 3, France.,European Associated Laboratory NeuroMicrobiota (INSERM/UCL), Bâtiment B - Pavillon Lefebvre, Toulouse Cedex 3, France
| | - Roshan Padmanabhan
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France
| | - Jason S Iacovoni
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France
| | - François Tercé
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France
| | - Patrice D Cani
- Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium
| | - Jean-François Tanti
- INSERM Unité 1065/Centre Méditerranéen de Médecine Moléculaire (C3M), Université Côte d'Azur, Nice, France
| | - Remy Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France
| | - Claude Knauf
- Toulouse III, Institut de Recherche en Santé Digestive (IRSD) Team 3, "Intestinal Neuroimmune Interactions" INSERM U1220, Université Paul Sabatier, Toulouse Cedex 3, France.,European Associated Laboratory NeuroMicrobiota (INSERM/UCL), Bâtiment B - Pavillon Lefebvre, Toulouse Cedex 3, France
| | - Mireille Cormont
- INSERM Unité 1065/Centre Méditerranéen de Médecine Moléculaire (C3M), Université Côte d'Azur, Nice, France
| | - Matteo Serino
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France .,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France
| |
Collapse
|
29
|
Bassols J, Serino M, Carreras-Badosa G, Burcelin R, Blasco-Baque V, Lopez-Bermejo A, Fernandez-Real JM. Gestational diabetes is associated with changes in placental microbiota and microbiome. Pediatr Res 2016; 80:777-784. [PMID: 27490741 DOI: 10.1038/pr.2016.155] [Citation(s) in RCA: 80] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2016] [Accepted: 06/03/2016] [Indexed: 12/18/2022]
Abstract
BACKGROUND The human microbiota is a modulator of the immune system. Variations in the placental microbiota could be related with pregnancy disorders. We profiled the placental microbiota and microbiome in women with gestational diabetes (GDM) and studied its relation to maternal metabolism and placental expression of anti-inflammatory cytokines. METHODS Placental microbiota and microbiome and expression of anti-inflammatory cytokines (IL10, TIMP3, ITGAX, and MRC1MR) were analyzed in placentas from women with GDM and from control women. Fasting insulin, glucose, O'Sullivan glucose, lipids, and blood cell counts were assessed at second and third trimester of pregnancy. RESULTS Bacteria belonging to the Pseudomonadales order and Acinetobacter genus showed lower relative abundance in women with GDM compared to control (P < 0.05). In GDM, lower abundance of placental Acinetobacter associated with a more adverse metabolic (higher O'Sullivan glucose) and inflammatory phenotype (lower blood eosinophil count and lower placental expression of IL10 and TIMP3) (P < 0.05 to P = 0.001). Calcium signaling pathway was increased in GDM placental microbiome. CONCLUSION A distinct microbiota profile and microbiome is present in GDM. Acinetobacter has been recently shown to induce IL-10 in mice. GDM could constitute a state of placental microbiota-driven altered immunologic tolerance, making placental microbiota a new target for therapy in GDM.
Collapse
Affiliation(s)
- Judit Bassols
- Department of Pediatrics, Dr. Josep Trueta Hospital and Girona Institute for Biomedical Research, Girona, Spain
| | - Matteo Serino
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse, France
| | - Gemma Carreras-Badosa
- Department of Pediatrics, Dr. Josep Trueta Hospital and Girona Institute for Biomedical Research, Girona, Spain
| | - Rémy Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse, France
| | - Vincent Blasco-Baque
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse, France.,Faculté de Chirurgie Dentaire de Toulouse, Université Paul Sabatier, Toulouse, France
| | - Abel Lopez-Bermejo
- Department of Pediatrics, Dr. Josep Trueta Hospital and Girona Institute for Biomedical Research, Girona, Spain
| | - José-Manuel Fernandez-Real
- Department of Endocrinology, Dr. Josep Trueta Hospital and Girona Institute for Biomedical Research and CIBERobn, Girona, Spain
| |
Collapse
|
30
|
Lelouvier B, Servant F, Païssé S, Brunet AC, Benyahya S, Serino M, Valle C, Ortiz MR, Puig J, Courtney M, Federici M, Fernández-Real JM, Burcelin R, Amar J. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. Hepatology 2016; 64:2015-2027. [PMID: 27639192 DOI: 10.1002/hep.28829] [Citation(s) in RCA: 168] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2016] [Revised: 07/21/2016] [Accepted: 09/01/2016] [Indexed: 12/20/2022]
Abstract
UNLABELLED The early detection of liver fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) is an important clinical need. In view of the suggested role played by bacterial translocation in liver disease and obesity, we sought to investigate the relationship between blood microbiota and liver fibrosis (LF) in European cohorts of patients with severe obesity. We carried out a cross-sectional study of obese patients, well characterized with respect to the severity of the NAFLD, in the cohort FLORINASH. This cohort has been divided into a discovery cohort comprising 50 Spanish patients and then in a validation cohort of 71 Italian patients. Blood bacterial DNA was analyzed both quantitatively by 16S ribosomal DNA (rDNA) quantitative polymerase chain reaction and qualitatively by 16S rDNA targeted metagenomic sequencing and functional metagenome prediction. Spanish plasma bile acid contents were analyzed by liquid chromatography/mass spectrometry. The 16S rDNA concentration was significantly higher in patients of the discovery cohort with LF. By 16S sequencing, we found specific differences in the proportion of several bacterial taxa in both blood and feces that correlate with the presence of LF, thus defining a specific signature of the liver disease. Several secondary/primary bile acid ratios were also decreased with LF in the discovery cohort. We confirmed, in the validation cohort, the correlation between blood 16S rDNA concentration and LF, whereas we did not confirm the specific bacterial taxa signature, despite a similar trend in patients with more-severe fibrosis. CONCLUSION Changes in blood microbiota are associated with LF in obese patients. Blood microbiota analysis provides potential biomarkers for the detection of LF in this population. (Hepatology 2016;64:2015-2027).
Collapse
Affiliation(s)
| | | | | | - Anne-Claire Brunet
- Vaiomer SAS, Labège, France.,IMT, Université Paul Sabatier, Toulouse, France
| | | | | | | | - Maria Rosa Ortiz
- Department of Diabetes, Endocrinology, and Nutrition, IDIBGI, Girona, Spain - CIBER Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Josep Puig
- Department of Radiology, IDI, IDIBGI, Girona, Spain
| | | | - Massimo Federici
- Department of Systems Medicine and Center for Atherosclerosis, University of Rome "Tor Vergata", Rome, Italy
| | - José-Manuel Fernández-Real
- Department of Diabetes, Endocrinology, and Nutrition, IDIBGI, Girona, Spain - CIBER Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Rémy Burcelin
- Vaiomer SAS, Labège, France.,INSERM U1048, I2MC, Toulouse, France
| | - Jacques Amar
- Vaiomer SAS, Labège, France.,INSERM U1048, I2MC, Toulouse, France.,Rangueil Hospital, Department of Therapeutics, Toulouse, France
| |
Collapse
|
31
|
Branchereau M, Reichardt F, Loubieres P, Marck P, Waget A, Azalbert V, Colom A, Padmanabhan R, Iacovoni JS, Giry A, Tercé F, Heymes C, Burcelin R, Serino M, Blasco-Baque V. Periodontal dysbiosis linked to periodontitis is associated with cardiometabolic adaptation to high-fat diet in mice. Am J Physiol Gastrointest Liver Physiol 2016; 310:G1091-101. [PMID: 27033119 DOI: 10.1152/ajpgi.00424.2015] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/02/2015] [Accepted: 03/03/2016] [Indexed: 01/31/2023]
Abstract
Periodontitis and type 2 diabetes are connected pandemic diseases, and both are risk factors for cardiovascular complications. Nevertheless, the molecular factors relating these two chronic pathologies are poorly understood. We have shown that, in response to a long-term fat-enriched diet, mice present particular gut microbiota profiles related to three metabolic phenotypes: diabetic-resistant (DR), intermediate (Inter), and diabetic-sensitive (DS). Moreover, many studies suggest that a dysbiosis of periodontal microbiota could be associated with the incidence of metabolic and cardiac diseases. We investigated whether periodontitis together with the periodontal microbiota may also be associated with these different cardiometabolic phenotypes. We report that the severity of glucose intolerance is related to the severity of periodontitis and cardiac disorders. In detail, alveolar bone loss was more accentuated in DS than Inter, DR, and normal chow-fed mice. Molecular markers of periodontal inflammation, such as TNF-α and plasminogen activator inhibitor-1 mRNA levels, correlated positively with both alveolar bone loss and glycemic index. Furthermore, the periodontal microbiota of DR mice was dominated by the Streptococcaceae family of the phylum Firmicutes, whereas the periodontal microbiota of DS mice was characterized by increased Porphyromonadaceae and Prevotellaceae families. Moreover, in DS mice the periodontal microbiota was indicated by an abundance of the genera Prevotella and Tannerella, which are major periodontal pathogens. PICRUSt analysis of the periodontal microbiome highlighted that prenyltransferase pathways follow the cardiometabolic adaptation to a high-fat diet. Finally, DS mice displayed a worse cardiac phenotype, percentage of fractional shortening, heart rhythm, and left ventricle weight-to-tibia length ratio than Inter and DR mice. Together, our data show that periodontitis combined with particular periodontal microbiota and microbiome is associated with metabolic adaptation to a high-fat diet related to the severity of cardiometabolic alteration.
Collapse
Affiliation(s)
- Maxime Branchereau
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - François Reichardt
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Pascale Loubieres
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France; Faculté de Chirurgie-Dentaire de Toulouse, Toulouse, France; and
| | - Pauline Marck
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Aurélie Waget
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Vincent Azalbert
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - André Colom
- Equipe Intéraction Mycobactériennes avec les Cellules Hôtes, Institute of Pharmacology and Structural Biology, Centre National de la Recherche Scientifique, Toulouse, France
| | - Roshan Padmanabhan
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Jason S Iacovoni
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Anaïs Giry
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - François Tercé
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Christophe Heymes
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Remy Burcelin
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Matteo Serino
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Vincent Blasco-Baque
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France; Faculté de Chirurgie-Dentaire de Toulouse, Toulouse, France; and
| |
Collapse
|
32
|
Fernandez-Real JM, Serino M, Blasco G, Puig J, Daunis-i-Estadella J, Ricart W, Burcelin R, Fernández-Aranda F, Portero-Otin M. Gut Microbiota Interacts With Brain Microstructure and Function. J Clin Endocrinol Metab 2015; 100:4505-13. [PMID: 26445114 DOI: 10.1210/jc.2015-3076] [Citation(s) in RCA: 101] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
CONTEXT Evidence from animals suggests that gut microbiota affects brain structure and function but evidence in humans is scarce. OBJECTIVE This study sought to evaluate potential interactions among gut microbiota composition, brain microstructure, and cognitive tests in obese and nonobese subjects. DESIGN, SETTING, AND PARTICIPANTS This was a cross-sectional study at a tertiary hospital including 20 consecutive obese and 19 nonobese subjects similar in age and sex. MAIN OUTCOME MEASURES Gut microbiota (16S bacterial gene pyrosequencing), brain microstructure (diffusion tensor imaging of brain white and gray matter and R2* sequences in magnetic resonance imaging) and cognitive tests. RESULTS Hierarchical clustering revealed a specific gut microbiota-brain map profile for obese individuals who could be discriminated from nonobese subjects (accuracy of 0.81). Strikingly, Shannon index was linked to R2* and fractional anisotropy of the hypothalamus, caudate nucleus, and hippocampus, suggesting sparing of these brain structures with increased bacterial biodiversity. Microbiota profile also clustered with cognitive function. The relative abundance of Actinobacteria phylum was linked not only to magnetic resonance imaging diffusion tensor imaging variables in the thalamus, hypothalamus, and amygdala but also to cognitive test scores related to speed, attention, and cognitive flexibility. CONCLUSIONS In sum, obesity status affects microbiota-brain microstructure and function crosstalk.
Collapse
Affiliation(s)
- José-Manuel Fernandez-Real
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| | - Matteo Serino
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| | - Gerard Blasco
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| | - Josep Puig
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| | - Josep Daunis-i-Estadella
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| | - Wifredo Ricart
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| | - Remy Burcelin
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| | - Fernando Fernández-Aranda
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| | - Manuel Portero-Otin
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| |
Collapse
|
33
|
Denou E, Lolmède K, Garidou L, Pomie C, Chabo C, Lau TC, Fullerton MD, Nigro G, Zakaroff-Girard A, Luche E, Garret C, Serino M, Amar J, Courtney M, Cavallari JF, Henriksbo BD, Barra NG, Foley KP, McPhee JB, Duggan BM, O'Neill HM, Lee AJ, Sansonetti P, Ashkar AA, Khan WI, Surette MG, Bouloumié A, Steinberg GR, Burcelin R, Schertzer JD. Defective NOD2 peptidoglycan sensing promotes diet-induced inflammation, dysbiosis, and insulin resistance. EMBO Mol Med 2015; 7:259-74. [PMID: 25666722 PMCID: PMC4364944 DOI: 10.15252/emmm.201404169] [Citation(s) in RCA: 136] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Pattern recognition receptors link metabolite and bacteria-derived inflammation to insulin resistance during obesity. We demonstrate that NOD2 detection of bacterial cell wall peptidoglycan (PGN) regulates metabolic inflammation and insulin sensitivity. An obesity-promoting high-fat diet (HFD) increased NOD2 in hepatocytes and adipocytes, and NOD2(-/-) mice have increased adipose tissue and liver inflammation and exacerbated insulin resistance during a HFD. This effect is independent of altered adiposity or NOD2 in hematopoietic-derived immune cells. Instead, increased metabolic inflammation and insulin resistance in NOD2(-/-) mice is associated with increased commensal bacterial translocation from the gut into adipose tissue and liver. An intact PGN-NOD2 sensing system regulated gut mucosal bacterial colonization and a metabolic tissue dysbiosis that is a potential trigger for increased metabolic inflammation and insulin resistance. Gut dysbiosis in HFD-fed NOD2(-/-) mice is an independent and transmissible factor that contributes to metabolic inflammation and insulin resistance when transferred to WT, germ-free mice. These findings warrant scrutiny of bacterial component detection, dysbiosis, and protective immune responses in the links between inflammatory gut and metabolic diseases, including diabetes.
Collapse
Affiliation(s)
- Emmanuel Denou
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
| | - Karine Lolmède
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France Université Paul Sabatier (UPS) Unité Mixte de Recherche (UMR) 1048 Institut des Maladies Métaboliques et Cardiovasculaires (I2MC) Team 1: «stroma-vascular cells of adipose tissue», Toulouse, France
| | - Lucile Garidou
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France Université Paul Sabatier (UPS) Unité Mixte de Recherche (UMR) 1048 Institut des Maladies Métaboliques et Cardiovasculaires (I2MC) Team 2: «Intestinal Risk Factors, Diabetes, Dyslipidemia», Toulouse Cedex 4, France
| | - Celine Pomie
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France Université Paul Sabatier (UPS) Unité Mixte de Recherche (UMR) 1048 Institut des Maladies Métaboliques et Cardiovasculaires (I2MC) Team 2: «Intestinal Risk Factors, Diabetes, Dyslipidemia», Toulouse Cedex 4, France
| | - Chantal Chabo
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France Université Paul Sabatier (UPS) Unité Mixte de Recherche (UMR) 1048 Institut des Maladies Métaboliques et Cardiovasculaires (I2MC) Team 2: «Intestinal Risk Factors, Diabetes, Dyslipidemia», Toulouse Cedex 4, France VAIOMER SAS, Prologue Biotech, Labège, France
| | - Trevor C Lau
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
| | - Morgan D Fullerton
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Giulia Nigro
- Unité de Pathogénie Microbienne Moléculaire and Unité INSERM 786 Institut Pasteur, Paris, France
| | - Alexia Zakaroff-Girard
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France Université Paul Sabatier (UPS) Unité Mixte de Recherche (UMR) 1048 Institut des Maladies Métaboliques et Cardiovasculaires (I2MC) Team 1: «stroma-vascular cells of adipose tissue», Toulouse, France
| | - Elodie Luche
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France Université Paul Sabatier (UPS) Unité Mixte de Recherche (UMR) 1048 Institut des Maladies Métaboliques et Cardiovasculaires (I2MC) Team 2: «Intestinal Risk Factors, Diabetes, Dyslipidemia», Toulouse Cedex 4, France
| | - Céline Garret
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France Université Paul Sabatier (UPS) Unité Mixte de Recherche (UMR) 1048 Institut des Maladies Métaboliques et Cardiovasculaires (I2MC) Team 2: «Intestinal Risk Factors, Diabetes, Dyslipidemia», Toulouse Cedex 4, France
| | - Matteo Serino
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France Université Paul Sabatier (UPS) Unité Mixte de Recherche (UMR) 1048 Institut des Maladies Métaboliques et Cardiovasculaires (I2MC) Team 2: «Intestinal Risk Factors, Diabetes, Dyslipidemia», Toulouse Cedex 4, France
| | - Jacques Amar
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France Université Paul Sabatier (UPS) Unité Mixte de Recherche (UMR) 1048 Institut des Maladies Métaboliques et Cardiovasculaires (I2MC) Team 2: «Intestinal Risk Factors, Diabetes, Dyslipidemia», Toulouse Cedex 4, France
| | | | - Joseph F Cavallari
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
| | - Brandyn D Henriksbo
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
| | - Nicole G Barra
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
| | - Kevin P Foley
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
| | - Joseph B McPhee
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
| | - Brittany M Duggan
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
| | - Hayley M O'Neill
- Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Amanda J Lee
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
| | - Philippe Sansonetti
- Unité de Pathogénie Microbienne Moléculaire and Unité INSERM 786 Institut Pasteur, Paris, France
| | - Ali A Ashkar
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
| | - Waliul I Khan
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada Farncombe Family Digestive Health Research Institute McMaster University, Hamilton, ON, Canada
| | - Michael G Surette
- Department of Medicine, McMaster University, Hamilton, ON, Canada Farncombe Family Digestive Health Research Institute McMaster University, Hamilton, ON, Canada
| | - Anne Bouloumié
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France Université Paul Sabatier (UPS) Unité Mixte de Recherche (UMR) 1048 Institut des Maladies Métaboliques et Cardiovasculaires (I2MC) Team 1: «stroma-vascular cells of adipose tissue», Toulouse, France
| | | | - Rémy Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France Université Paul Sabatier (UPS) Unité Mixte de Recherche (UMR) 1048 Institut des Maladies Métaboliques et Cardiovasculaires (I2MC) Team 2: «Intestinal Risk Factors, Diabetes, Dyslipidemia», Toulouse Cedex 4, France
| | - Jonathan D Schertzer
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
| |
Collapse
|
34
|
Garidou L, Pomié C, Klopp P, Waget A, Charpentier J, Aloulou M, Giry A, Serino M, Stenman L, Lahtinen S, Dray C, Iacovoni JS, Courtney M, Collet X, Amar J, Servant F, Lelouvier B, Valet P, Eberl G, Fazilleau N, Douin-Echinard V, Heymes C, Burcelin R. The Gut Microbiota Regulates Intestinal CD4 T Cells Expressing RORγt and Controls Metabolic Disease. Cell Metab 2015; 22:100-12. [PMID: 26154056 DOI: 10.1016/j.cmet.2015.06.001] [Citation(s) in RCA: 213] [Impact Index Per Article: 23.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/10/2014] [Revised: 03/31/2015] [Accepted: 06/02/2015] [Indexed: 02/06/2023]
Abstract
A high-fat diet (HFD) induces metabolic disease and low-grade metabolic inflammation in response to changes in the intestinal microbiota through as-yet-unknown mechanisms. Here, we show that a HFD-derived ileum microbiota is responsible for a decrease in Th17 cells of the lamina propria in axenic colonized mice. The HFD also changed the expression profiles of intestinal antigen-presenting cells and their ability to generate Th17 cells in vitro. Consistent with these data, the metabolic phenotype was mimicked in RORγt-deficient mice, which lack IL17 and IL22 function, and in the adoptive transfer experiment of T cells from RORγt-deficient mice into Rag1-deficient mice. We conclude that the microbiota of the ileum regulates Th17 cell homeostasis in the small intestine and determines the outcome of metabolic disease.
Collapse
Affiliation(s)
- Lucile Garidou
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048 F-31432 Toulouse, France; Université Paul Sabatier, F-31432 Toulouse, France.
| | - Céline Pomié
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048 F-31432 Toulouse, France; Université Paul Sabatier, F-31432 Toulouse, France
| | - Pascale Klopp
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048 F-31432 Toulouse, France; Université Paul Sabatier, F-31432 Toulouse, France
| | - Aurélie Waget
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048 F-31432 Toulouse, France; Université Paul Sabatier, F-31432 Toulouse, France
| | - Julie Charpentier
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048 F-31432 Toulouse, France; Université Paul Sabatier, F-31432 Toulouse, France
| | - Meryem Aloulou
- Université Paul Sabatier, F-31432 Toulouse, France; Centre de Physiopathologie de Toulouse Purpan, INSERM U1043, F-31300 Toulouse, France; CNRS, UMR5282, F-31300 Toulouse, France
| | - Anaïs Giry
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048 F-31432 Toulouse, France; Université Paul Sabatier, F-31432 Toulouse, France
| | - Matteo Serino
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048 F-31432 Toulouse, France; Université Paul Sabatier, F-31432 Toulouse, France
| | - Lotta Stenman
- Danisco Sweeteners Oy Sokeritehtaantie 20 FI-02460 Kantvik, Finland
| | - Sampo Lahtinen
- Danisco Sweeteners Oy Sokeritehtaantie 20 FI-02460 Kantvik, Finland
| | - Cedric Dray
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048 F-31432 Toulouse, France; Université Paul Sabatier, F-31432 Toulouse, France
| | - Jason S Iacovoni
- Plateau de Bioinformatique et Biostatistique, INSERM UMR1048, F-31432 Toulouse, France
| | - Michael Courtney
- Vaiomer SAS, 516 Rue Pierre et Marie Curie, F-31670 Labège, France
| | - Xavier Collet
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048 F-31432 Toulouse, France; Université Paul Sabatier, F-31432 Toulouse, France
| | - Jacques Amar
- Université Paul Sabatier, F-31432 Toulouse, France; Hôpital Rangueil, Département Thérapeutique, F-31059 Toulouse, France
| | - Florence Servant
- Vaiomer SAS, 516 Rue Pierre et Marie Curie, F-31670 Labège, France
| | | | - Philippe Valet
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048 F-31432 Toulouse, France; Université Paul Sabatier, F-31432 Toulouse, France
| | - Gérard Eberl
- Institut Pasteur, Unité de Développement des Tissus Lymphoïdes, F-75724 Paris, France
| | - Nicolas Fazilleau
- Université Paul Sabatier, F-31432 Toulouse, France; Centre de Physiopathologie de Toulouse Purpan, INSERM U1043, F-31300 Toulouse, France; CNRS, UMR5282, F-31300 Toulouse, France
| | - Victorine Douin-Echinard
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048 F-31432 Toulouse, France; Université Paul Sabatier, F-31432 Toulouse, France
| | - Christophe Heymes
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048 F-31432 Toulouse, France; Université Paul Sabatier, F-31432 Toulouse, France
| | - Rémy Burcelin
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048 F-31432 Toulouse, France; Université Paul Sabatier, F-31432 Toulouse, France.
| |
Collapse
|
35
|
Serino M, Blasco-Baque V, Nicolas S, Burcelin R. Managing the manager: Gut microbes, stem cells and metabolism. Diabetes & Metabolism 2014; 40:186-90. [DOI: 10.1016/j.diabet.2013.12.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/04/2013] [Revised: 12/09/2013] [Accepted: 12/10/2013] [Indexed: 12/18/2022]
|
36
|
Maselli A, Melandri A, Nava L, Mundell CG, Kawai N, Campana S, Covino S, Cummings JR, Cusumano G, Evans PA, Ghirlanda G, Ghisellini G, Guidorzi C, Kobayashi S, Kuin P, La Parola V, Mangano V, Oates S, Sakamoto T, Serino M, Virgili F, Zhang BB, Barthelmy S, Beardmore A, Bernardini MG, Bersier D, Burrows D, Calderone G, Capalbi M, Chiang J, D’Avanzo P, D’Elia V, De Pasquale M, Fugazza D, Gehrels N, Gomboc A, Harrison R, Hanayama H, Japelj J, Kennea J, Kopac D, Kouveliotou C, Kuroda D, Levan A, Malesani D, Marshall F, Nousek J, O’Brien P, Osborne JP, Pagani C, Page KL, Page M, Perri M, Pritchard T, Romano P, Saito Y, Sbarufatti B, Salvaterra R, Steele I, Tanvir N, Vianello G, Wiegand B, Wiersema K, Yatsu Y, Yoshii T, Tagliaferri G. GRB 130427A: A Nearby Ordinary Monster. Science 2014; 343:48-51. [DOI: 10.1126/science.1242279] [Citation(s) in RCA: 89] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Affiliation(s)
- A. Maselli
- Istituto Nazionale di Astrofisica (INAF)–Istituto di Astrofisica Spaziale e Fisica Cosmica (IASF) Palermo, Via Ugo La Malfa 153 I-90146 Palermo, Italy
| | - A. Melandri
- INAF–Osservatorio Astronomico di Brera, via E. Bianchi 46, I-23807 Merate, Italy
| | - L. Nava
- INAF–Osservatorio Astronomico di Brera, via E. Bianchi 46, I-23807 Merate, Italy
- AstroParticule et Cosmologie, Université Paris Diderot, CNRS/IN2P3, Commissariat à l'Energie Atomique et aux Energies Alternatives/Institut de Recherches sur les lois Fondamentales de l’Univers, Observatoire de Paris, Sorbonne Paris Cité, France
| | - C. G. Mundell
- Astrophysics Research Institute, Liverpool John Moores University, Liverpool Science Park, 146 Brownlow Hill, Liverpool L3 5RF, UK
| | - N. Kawai
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8551, Japan
- Coordinated Space Observation and Experiment Research Group, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S. Campana
- INAF–Osservatorio Astronomico di Brera, via E. Bianchi 46, I-23807 Merate, Italy
| | - S. Covino
- INAF–Osservatorio Astronomico di Brera, via E. Bianchi 46, I-23807 Merate, Italy
| | - J. R. Cummings
- University of Maryland, Baltimore County/Center for Research and Exploration in Space Science & Technology/NASA Goddard Space Flight Center, Code 661, Greenbelt, MD 20771, USA
| | - G. Cusumano
- Istituto Nazionale di Astrofisica (INAF)–Istituto di Astrofisica Spaziale e Fisica Cosmica (IASF) Palermo, Via Ugo La Malfa 153 I-90146 Palermo, Italy
| | - P. A. Evans
- Department of Physics and Astronomy, University of Leicester, Leicester, LE1 7RH, UK
| | - G. Ghirlanda
- INAF–Osservatorio Astronomico di Brera, via E. Bianchi 46, I-23807 Merate, Italy
| | - G. Ghisellini
- INAF–Osservatorio Astronomico di Brera, via E. Bianchi 46, I-23807 Merate, Italy
| | - C. Guidorzi
- Department of Physics, University of Ferrara, via Saragat 1, I-44122, Ferrara, Italy
| | - S. Kobayashi
- Astrophysics Research Institute, Liverpool John Moores University, Liverpool Science Park, 146 Brownlow Hill, Liverpool L3 5RF, UK
| | - P. Kuin
- Mullard Space Science Laboratory, University College London, Holmbury St. Mary, Dorking, Surrey RH5 6NT, UK
| | - V. La Parola
- Istituto Nazionale di Astrofisica (INAF)–Istituto di Astrofisica Spaziale e Fisica Cosmica (IASF) Palermo, Via Ugo La Malfa 153 I-90146 Palermo, Italy
| | - V. Mangano
- Istituto Nazionale di Astrofisica (INAF)–Istituto di Astrofisica Spaziale e Fisica Cosmica (IASF) Palermo, Via Ugo La Malfa 153 I-90146 Palermo, Italy
- Department of Astronomy and Astrophysics, Pennsylvania State University, 525 Davey Lab, University Park, PA 16802, USA
| | - S. Oates
- Mullard Space Science Laboratory, University College London, Holmbury St. Mary, Dorking, Surrey RH5 6NT, UK
| | - T. Sakamoto
- Department of Physics and Mathematics, Aoyama Gakuin University, 5-10-1 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa 252-5258, Japan
| | - M. Serino
- Coordinated Space Observation and Experiment Research Group, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - F. Virgili
- Astrophysics Research Institute, Liverpool John Moores University, Liverpool Science Park, 146 Brownlow Hill, Liverpool L3 5RF, UK
| | - B.-B. Zhang
- Department of Astronomy and Astrophysics, Pennsylvania State University, 525 Davey Lab, University Park, PA 16802, USA
| | - S. Barthelmy
- NASA Goddard Space Flight Center, Greenbelt, MD 20771, USA
| | - A. Beardmore
- Department of Physics and Astronomy, University of Leicester, Leicester, LE1 7RH, UK
| | - M. G. Bernardini
- INAF–Osservatorio Astronomico di Brera, via E. Bianchi 46, I-23807 Merate, Italy
| | - D. Bersier
- Astrophysics Research Institute, Liverpool John Moores University, Liverpool Science Park, 146 Brownlow Hill, Liverpool L3 5RF, UK
| | - D. Burrows
- Department of Astronomy and Astrophysics, Pennsylvania State University, 525 Davey Lab, University Park, PA 16802, USA
| | - G. Calderone
- INAF–Osservatorio Astronomico di Brera, via E. Bianchi 46, I-23807 Merate, Italy
- Dipartimento di Fisica “G. Occhialini,” Università di Milano-Bicocca, Piazza della Scienza 3, I-20126 Milano, Italy
| | - M. Capalbi
- Istituto Nazionale di Astrofisica (INAF)–Istituto di Astrofisica Spaziale e Fisica Cosmica (IASF) Palermo, Via Ugo La Malfa 153 I-90146 Palermo, Italy
| | - J. Chiang
- W. W. Hansen Experimental Physics Laboratory, Kavli Institute for Particle Astrophysics and Cosmology, Department of Physics, and SLAC National Accelerator Laboratory, Stanford University, Stanford, CA 94305, USA
| | - P. D’Avanzo
- INAF–Osservatorio Astronomico di Brera, via E. Bianchi 46, I-23807 Merate, Italy
| | - V. D’Elia
- INAF/Rome Astronomical Observatory, via Frascati 33, 00040 Monteporzio Catone (Roma), Italy
- Agenzia Spaziale Italiana (ASI) Science Data Centre, Via Galileo Galilei, 00044 Frascati (Roma), Italy
| | - M. De Pasquale
- Mullard Space Science Laboratory, University College London, Holmbury St. Mary, Dorking, Surrey RH5 6NT, UK
| | - D. Fugazza
- INAF–Osservatorio Astronomico di Brera, via E. Bianchi 46, I-23807 Merate, Italy
| | - N. Gehrels
- NASA Goddard Space Flight Center, Greenbelt, MD 20771, USA
| | - A. Gomboc
- Faculty of Mathematics and Physics, University of Ljubljana, Jadranska 19 1000, Ljubljana, Slovenia
- Centre of Excellence Space-si, Askerceva cesta 12, 1000 Ljubljana, Slovenia
| | - R. Harrison
- Astrophysics Research Institute, Liverpool John Moores University, Liverpool Science Park, 146 Brownlow Hill, Liverpool L3 5RF, UK
| | - H. Hanayama
- Ishigakijima Astronomical Observatory, National Astronomical Observatory of Japan, 1024-1 Arakawa, Ishigaki, Okinawa 907-0024, Japan
| | - J. Japelj
- Faculty of Mathematics and Physics, University of Ljubljana, Jadranska 19 1000, Ljubljana, Slovenia
| | - J. Kennea
- Department of Astronomy and Astrophysics, Pennsylvania State University, 525 Davey Lab, University Park, PA 16802, USA
| | - D. Kopac
- Faculty of Mathematics and Physics, University of Ljubljana, Jadranska 19 1000, Ljubljana, Slovenia
| | - C. Kouveliotou
- Space Science Office, VP62, NASA/Marshall Space Flight Center, Huntsville, AL 35812, USA
| | - D. Kuroda
- Okayama Astrophysical Observatory, National Astronomical Observatory of Japan, 3037-5 Honjo, Kamogata, Asaguchi, Okayama 719-0232
| | - A. Levan
- Department of Physics, University of Warwick, Coventry CV4 7AL, UK
| | - D. Malesani
- Dark Cosmology Centre (DARK), Niels Bohr Institute, University of Copenhagen, Juliane Maries Vej 30, 2100 Copenhagen, Denmark
| | - F. Marshall
- NASA Goddard Space Flight Center, Greenbelt, MD 20771, USA
| | - J. Nousek
- Department of Astronomy and Astrophysics, Pennsylvania State University, 525 Davey Lab, University Park, PA 16802, USA
| | - P. O’Brien
- Department of Physics and Astronomy, University of Leicester, Leicester, LE1 7RH, UK
| | - J. P. Osborne
- Department of Physics and Astronomy, University of Leicester, Leicester, LE1 7RH, UK
| | - C. Pagani
- Department of Physics and Astronomy, University of Leicester, Leicester, LE1 7RH, UK
| | - K. L. Page
- Department of Physics and Astronomy, University of Leicester, Leicester, LE1 7RH, UK
| | - M. Page
- Mullard Space Science Laboratory, University College London, Holmbury St. Mary, Dorking, Surrey RH5 6NT, UK
| | - M. Perri
- INAF/Rome Astronomical Observatory, via Frascati 33, 00040 Monteporzio Catone (Roma), Italy
- Agenzia Spaziale Italiana (ASI) Science Data Centre, Via Galileo Galilei, 00044 Frascati (Roma), Italy
| | - T. Pritchard
- Department of Astronomy and Astrophysics, Pennsylvania State University, 525 Davey Lab, University Park, PA 16802, USA
| | - P. Romano
- Istituto Nazionale di Astrofisica (INAF)–Istituto di Astrofisica Spaziale e Fisica Cosmica (IASF) Palermo, Via Ugo La Malfa 153 I-90146 Palermo, Italy
| | - Y. Saito
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8551, Japan
| | - B. Sbarufatti
- INAF–Osservatorio Astronomico di Brera, via E. Bianchi 46, I-23807 Merate, Italy
- Department of Astronomy and Astrophysics, Pennsylvania State University, 525 Davey Lab, University Park, PA 16802, USA
| | - R. Salvaterra
- INAF-IASF Milano, via E. Bassini 15, I-20133 Milano, Italy
| | - I. Steele
- Astrophysics Research Institute, Liverpool John Moores University, Liverpool Science Park, 146 Brownlow Hill, Liverpool L3 5RF, UK
| | - N. Tanvir
- Department of Physics and Astronomy, University of Leicester, Leicester, LE1 7RH, UK
| | - G. Vianello
- W. W. Hansen Experimental Physics Laboratory, Kavli Institute for Particle Astrophysics and Cosmology, Department of Physics, and SLAC National Accelerator Laboratory, Stanford University, Stanford, CA 94305, USA
| | - B. Wiegand
- NASA Goddard Space Flight Center, Greenbelt, MD 20771, USA
| | - K. Wiersema
- Department of Physics and Astronomy, University of Leicester, Leicester, LE1 7RH, UK
| | - Y. Yatsu
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8551, Japan
| | - T. Yoshii
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8551, Japan
| | - G. Tagliaferri
- INAF–Osservatorio Astronomico di Brera, via E. Bianchi 46, I-23807 Merate, Italy
| |
Collapse
|
37
|
Moreno-Navarrete JM, Escoté X, Ortega F, Serino M, Campbell M, Michalski MC, Laville M, Xifra G, Luche E, Domingo P, Sabater M, Pardo G, Waget A, Salvador J, Giralt M, Rodriguez-Hermosa JI, Camps M, Kolditz CI, Viguerie N, Galitzky J, Decaunes P, Ricart W, Frühbeck G, Villarroya F, Mingrone G, Langin D, Zorzano A, Vidal H, Vendrell J, Burcelin R, Vidal-Puig A, Fernández-Real JM. A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction. Diabetologia 2013; 56:2524-37. [PMID: 23963324 DOI: 10.1007/s00125-013-3015-9] [Citation(s) in RCA: 95] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2013] [Accepted: 07/10/2013] [Indexed: 01/12/2023]
Abstract
AIMS/HYPOTHESIS Circulating lipopolysaccharide-binding protein (LBP) is an acute-phase reactant known to be increased in obesity. We hypothesised that LBP is produced by adipose tissue (AT) in association with obesity. METHODS LBP mRNA and LBP protein levels were analysed in AT from three cross-sectional (n = 210, n = 144 and n = 28) and three longitudinal (n = 8, n = 25, n = 20) human cohorts; in AT from genetically manipulated mice; in isolated adipocytes; and in human and murine cell lines. The effects of a high-fat diet and exposure to lipopolysaccharide (LPS) and peroxisome proliferator-activated receptor (PPAR)γ agonist were explored. Functional in vitro and ex vivo experiments were also performed. RESULTS LBP synthesis and release was demonstrated to increase with adipocyte differentiation in human and mouse AT, isolated adipocytes and human and mouse cell lines (Simpson-Golabi-Behmel syndrome [SGBS], human multipotent adipose-derived stem [hMAD] and 3T3-L1 cells). AT LBP expression was robustly associated with inflammatory markers and increased with metabolic deterioration and insulin resistance in two independent cross-sectional human cohorts. AT LBP also increased longitudinally with weight gain and excessive fat accretion in both humans and mice, and decreased with weight loss (in two other independent cohorts), in humans with acquired lipodystrophy, and after ex vivo exposure to PPARγ agonist. Inflammatory agents such as LPS and TNF-α led to increased AT LBP expression in vivo in mice and in vitro, while this effect was prevented in Cd14-knockout mice. Functionally, LBP knockdown using short hairpin (sh)RNA or anti-LBP antibody led to increases in markers of adipogenesis and decreased adipocyte inflammation in human adipocytes. CONCLUSIONS/INTERPRETATION Collectively, these findings suggest that LBP might have an essential role in inflammation- and obesity-associated AT dysfunction.
Collapse
Affiliation(s)
- José María Moreno-Navarrete
- Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), Hospital Universitari 'Dr Josep Trueta', Carretera de França s/n, 17007, Girona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Serino M, Fernández-Real JM, Fuentes EG, Queipo-Ortuño M, Moreno-Navarrete JM, Sánchez Á, Burcelin R, Tinahones F. The gut microbiota profile is associated with insulin action in humans. Acta Diabetol 2013; 50:753-61. [PMID: 22711164 PMCID: PMC3898146 DOI: 10.1007/s00592-012-0410-5] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2012] [Accepted: 05/29/2012] [Indexed: 12/25/2022]
Abstract
The role of the gut microbiota in the induction of metabolic diseases has now been increasingly recognized worldwide. Indeed, a specific gut microbiota has been shown to characterize lean versus obese phenotypes both in humans and mice. We have also recently demonstrated that a precise gut microbiota is associated with the host's responsiveness to a high-fat diet. Therefore, we hypothesized that insulin resistance in humans could also be linked to a specific gut microbiota. To this aim, microbial DNA and RNA were extracted from the appendix contents of insulin-resistant versus insulin-sensitive obese subjects, matched for body mass index and age, and analyzed by DNA- and RNA-DGGE. Microbial DNA analysis showed that the patients fully segregated according to their degree of insulin action. Conversely, microbial RNA investigation showed that some degree of homology still existed between insulin-sensitive and insulin-resistant patients. Quantitative trait analysis, ordinary least squares regression, principal components regression, partial least squares, canonical correlation analysis, and canonical correspondence analysis also showed a net separation of the two phenotypes analyzed. We conclude that a specific gut microbial profile is associated with insulin action in humans.
Collapse
Affiliation(s)
- Matteo Serino
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), 31432 Toulouse Cedex 4, France
| | - José Manuel Fernández-Real
- Department of Diabetes Endocrinology and Nutrition, Institut d’Investigació Biomédica de Girona, and CIBER Fisiopatologia Obesidad y Nutricion (CB06/03/010), Instituto de Salud Carlos III, Girona, Spain
| | - Eduardo García Fuentes
- Service of Endocrinology and Nutrition, Hospital Clinico Universitario Virgen de Victoria de Malaga and CIBEROBN (CB06/03/010), Instituto de Salud Carlos III, Madrid, Spain
| | - Maribel Queipo-Ortuño
- Service of Endocrinology and Nutrition, Hospital Clinico Universitario Virgen de Victoria de Malaga and CIBEROBN (CB06/03/010), Instituto de Salud Carlos III, Madrid, Spain
| | - José María Moreno-Navarrete
- Department of Diabetes Endocrinology and Nutrition, Institut d’Investigació Biomédica de Girona, and CIBER Fisiopatologia Obesidad y Nutricion (CB06/03/010), Instituto de Salud Carlos III, Girona, Spain
| | - Álex Sánchez
- Statistics Department, Facultat de Biologia UB, University of Barcelona, Avda Diagonal 645, 08028 Barcelona, Spain
- Institut de Recerca, Hospital Universitari Vall’Hebron, Passeig Vall d’Hebron 112-119, 08035 Barcelona, Spain
| | - Rémy Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), 31432 Toulouse Cedex 4, France
| | - Francisco Tinahones
- Service of Endocrinology and Nutrition, Hospital Clinico Universitario Virgen de Victoria de Malaga and CIBEROBN (CB06/03/010), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
39
|
Burcelin R, Serino M, Chabo C, Garidou L, Pomié C, Courtney M, Amar J, Bouloumié A. Metagenome and metabolism: the tissue microbiota hypothesis. Diabetes Obes Metab 2013; 15 Suppl 3:61-70. [PMID: 24003922 DOI: 10.1111/dom.12157] [Citation(s) in RCA: 93] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/25/2013] [Accepted: 05/22/2013] [Indexed: 12/14/2022]
Abstract
Over the last decade, the research community has revealed the role of a new organ: the intestinal microbiota. It is considered as a symbiont that is part of our organism since, at birth, it educates the immune system and contributes to the development of the intestinal vasculature and most probably the nervous system. With the advent of new generation sequencing techniques, a catalogue of genes that belong to this microbiome has been established that lists more than 5 million non-redundant genes called the metagenome. Using germ free mice colonized with the microbiota from different origins, it has been formally demonstrated that the intestinal microbiota causes the onset of metabolic diseases. Further to the role of point mutations in our genome, the microbiota can explain the on-going worldwide pandemic of obesity and diabetes, its dissemination and family inheritance, as well as the diversity of the associated metabolic phenotypes. More recently, the discovery of bacterial DNA within host tissues, such as the liver, the adipose tissue and the blood, which establishes a tissue microbiota, introduces new opportunities to identify targets and predictive biomarkers based on the host to microbiota interaction, as well as to define new strategies for pharmacological, immunomodulatory vaccines and nutritional applications.
Collapse
Affiliation(s)
- Rémy Burcelin
- Institut National de Santé et de Recherche Médicale (INSERM), U1048, Toulouse, France.
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Luche E, Cousin B, Garidou L, Serino M, Waget A, Barreau C, André M, Valet P, Courtney M, Casteilla L, Burcelin R. Metabolic endotoxemia directly increases the proliferation of adipocyte precursors at the onset of metabolic diseases through a CD14-dependent mechanism. Mol Metab 2013; 2:281-91. [PMID: 24049740 DOI: 10.1016/j.molmet.2013.06.005] [Citation(s) in RCA: 71] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2013] [Revised: 06/18/2013] [Accepted: 06/21/2013] [Indexed: 01/17/2023] Open
Abstract
Metabolic endotoxemia triggers inflammation, targets cells from the stroma-vascular fraction of adipose depots, and metabolic disease. To identify these cells we here infused mice with lipopolysaccharides and showed by FACS analyses and BrdU staining that the number of small subcutaneous adipocytes, preadipocytes and macrophages increased in wild type but not in CD14-knockout (KO) mice. This mechanism was direct since in CD14KO mice grafted subcutaneously and simultaneously with fat pads from CD14KO and wild-type mice the concentration of cytokine mRNA was increased in the wild-type fat pad only. Conversely, the mRNA concentration of genes involved in glucose and lipid metabolism and the number of large adipocytes was reduced. Eventually, a pretreatment with LPS enhanced HFD-induced metabolic diseases. Altogether, these results show that metabolic endotoxemia increases the proliferation of preadipocytes through a CD14-dependent mechanism directly, without recruiting CD14-positive cells from non-adipose depot origin. This mechanism could precede the onset of metabolic diseases.
Collapse
Affiliation(s)
- Elodie Luche
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France ; Université Paul Sabatier, Toulouse, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Ortega FJ, Mercader JM, Moreno-Navarrete JM, Sabater M, Pueyo N, Valdés S, Ruiz B, Luche E, Serino M, Naon D, Ricart W, Botas P, Delgado E, Burcelin R, Frühbeck G, Bosch F, Mingrone G, Zorzano A, Fernández-Real JM. Erratum to: Targeting the association of calgranulin B (S100A9) with insulin resistance and type 2 diabetes. J Mol Med (Berl) 2013. [DOI: 10.1007/s00109-013-1014-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
42
|
Ortega FJ, Mercader JM, Moreno-Navarrete JM, Sabater M, Pueyo N, Valdés S, Ruiz B, Luche E, Serino M, Naon D, Ricart W, Botas P, Delgado E, Burcelin R, Frühbeck G, Bosch F, Mingrone G, Zorzano A, Fernández-Real JM. Targeting the association of calgranulin B (S100A9) with insulin resistance and type 2 diabetes. J Mol Med (Berl) 2012. [PMID: 23207880 DOI: 10.1007/s00109-012-0979-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Calgranulin B (S100A9) was recognized as a candidate type 2 diabetes (T2D) gene in the genomic profiling of muscle from a rodent model of T2D and identifying the human orthologs of genes localized in T2D susceptibility regions. Circulating and S100A9 expressions in muscle and adipose tissue, isolated fat cells, and mouse models were evaluated. A common 5'-upstream single-nucleotide polymorphism (SNP; rs3014866) for S100A9 was analyzed, as well as the effects of weight loss and treatments in vitro with recombinant S100A9. S100a9 expression was increased in muscle of diabetic mice (1.6-fold, p = 0.002), and in muscle from subjects with impaired glucose tolerance (∼4-fold, p = 0.028; n = 34). The rs3014866 SNP was associated with circulating S100A9 and the risk of T2D, having TT carriers at 28 % (p = 0.03) lower risk (n = 1,450). Indeed, increased circulating S100A9 (∼4-fold, p = 0.03; n = 206) and subcutaneous (2-fold, p = 0.01) and omental (1.4-fold, p = 0.04) S100A9 gene expressions (n = 83) in TT carriers run in parallel to decreased fasting glucose and glycated hemoglobin. Accordingly, metformin led to increased S100A9 mRNA in ex vivo-treated adipose tissue explants (n = 5/treatment). Otherwise, obese subjects showed a compensatory increase in circulating and S100A9 expressions in adipose (n = 126), as further demonstrated by decreased levels after diet- (-34 %, p = 0.002; n = 20) and surgery-induced (-58 %, p = 0.02; n = 8) weight loss. Lipopolysaccharide led to increased S100A9 in adipose from mice (n = 5/treatment) while recombinant S100A9 downregulated inflammation in adipocytes (n = 3/treatment). Current findings support the strategy of testing differentially expressed genes in mice and human orthologs associated with T2D. The increased S100A9 reported for obesity and insulin resistance may be envisioned as a compensatory mechanism for inflammation.
Collapse
Affiliation(s)
- Francisco J Ortega
- Department of Diabetes, Endocrinology and Nutrition (UDEN), Institut d'Investigació Biomédica de Girona (IdIBGi), CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III (ISCIII), Girona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Blasco-Baque V, Serino M, Vergnes JN, Riant E, Loubieres P, Arnal JF, Gourdy P, Sixou M, Burcelin R, Kemoun P. High-fat diet induces periodontitis in mice through lipopolysaccharides (LPS) receptor signaling: protective action of estrogens. PLoS One 2012; 7:e48220. [PMID: 23133617 PMCID: PMC3487901 DOI: 10.1371/journal.pone.0048220] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2012] [Accepted: 09/21/2012] [Indexed: 01/12/2023] Open
Abstract
Background A fat-enriched diet favors the development of gram negative bacteria in the intestine which is linked to the occurrence of type 2 diabetes (T2D). Interestingly, some pathogenic gram negative bacteria are commonly associated with the development of periodontitis which, like T2D, is characterized by a chronic low-grade inflammation. Moreover, estrogens have been shown to regulate glucose homeostasis via an LPS receptor dependent immune-modulation. In this study, we evaluated whether diet-induced metabolic disease would favor the development of periodontitis in mice. In addition, the regulatory role of estrogens in this process was assessed. Methods Four-week-old C57BL6/J WT and CD14 (part of the TLR-4 machinery for LPS-recognition) knock-out female mice were ovariectomised and subcutaneously implanted with pellets releasing either placebo or 17β-estradiol (E2). Mice were then fed with either a normal chow or a high-fat diet for four weeks. The development of diabetes was monitored by an intraperitoneal glucose-tolerance test and plasma insulin concentration while periodontitis was assessed by identification of pathogens, quantification of periodontal soft tissue inflammation and alveolar bone loss. Results The fat-enriched diet increased the prevalence of periodontal pathogenic microbiota like Fusobacterium nucleatum and Prevotella intermedia, gingival inflammation and alveolar bone loss. E2 treatment prevented this effect and CD14 knock-out mice resisted high-fat diet-induced periodontal defects. Conclusions/Significance Our data show that mice fed with a diabetogenic diet developed defects and microflora of tooth supporting-tissues typically associated with periodontitis. Moreover, our results suggest a causal link between the activation of the LPS pathway on innate immunity by periodontal microbiota and HFD-induced periodontitis, a pathophysiological mechanism that could be targeted by estrogens.
Collapse
Affiliation(s)
- Vincent Blasco-Baque
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Université Paul Sabatier, Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
- L.U. 51, Parodontites et Maladies Générales, Université Paul Sabatier, Faculté de Chirurgie Dentaire, 3, Chemin des Maraîchers, Toulouse, France
| | - Matteo Serino
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Université Paul Sabatier, Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
| | - Jean-Noël Vergnes
- L.U. 51, Parodontites et Maladies Générales, Université Paul Sabatier, Faculté de Chirurgie Dentaire, 3, Chemin des Maraîchers, Toulouse, France
| | - Elodie Riant
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Université Paul Sabatier, Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
| | - Pascale Loubieres
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Université Paul Sabatier, Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
- L.U. 51, Parodontites et Maladies Générales, Université Paul Sabatier, Faculté de Chirurgie Dentaire, 3, Chemin des Maraîchers, Toulouse, France
| | - Jean-François Arnal
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Université Paul Sabatier, Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
| | - Pierre Gourdy
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Université Paul Sabatier, Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
| | - Michel Sixou
- L.U. 51, Parodontites et Maladies Générales, Université Paul Sabatier, Faculté de Chirurgie Dentaire, 3, Chemin des Maraîchers, Toulouse, France
| | - Rémy Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Université Paul Sabatier, Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
- * E-mail: (RB); (PK)
| | - Philippe Kemoun
- L.U. 51, Parodontites et Maladies Générales, Université Paul Sabatier, Faculté de Chirurgie Dentaire, 3, Chemin des Maraîchers, Toulouse, France
- * E-mail: (RB); (PK)
| |
Collapse
|
44
|
Blasco-Baque V, Serino M, Burcelin R. [Metabolic therapy at the edge between human hosts and gut microbes]. Ann Pharm Fr 2012; 71:34-41. [PMID: 23348854 DOI: 10.1016/j.pharma.2012.08.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2012] [Revised: 08/28/2012] [Accepted: 08/29/2012] [Indexed: 12/26/2022]
Abstract
Personalized medicine is becoming day-after-day more urgent taking into account the great diversity characterizing patients affected by a given pathology, especially metabolic diseases. In fact, antidiabetic/obesity treatments have shown a reduced or no effect at all in some patients, representing a major challenge physicians have to face worldwide. Therefore, efforts have to be put to identify individual factors affecting our susceptibility towards a given medication. In that regard, gut microbiota may stand for the missing piece of the metabolic puzzle regulating host response, since its role in the induction of metabolic diseases has now been achieved. In fact, we firstly provided a bacterial explanation for the low-grade chronic inflammation featuring metabolic diseases, by showing the lipopolysaccharide as a trigger and risk factor of such pathologies. However, despite similar lineages of microbes characterize the gut of people, important differences still remain, which may be responsible for opposite effect of treatments such as pre- or probiotics, whose efficacy seems to be governed by the own gut microbiota of subjects. We have recently shown that gut microbiota is associated to the inclination to resist or not high-fat diet-induced type 2 diabetes in mice. In addition, the direct targeting of gut microbes by dietary fibers reversed the observed metabolic phenotype. These results, together with the literature, strongly suggest gut microbiota as a new target for the development of personalized metabolic therapy.
Collapse
Affiliation(s)
- V Blasco-Baque
- Institut national de la santé et de la recherche médicale (Inserm), UMR 1048, Toulouse, France
| | | | | |
Collapse
|
45
|
Blasco-Baque V, Kémoun P, Loubieres P, Roumieux M, Heymes C, Serino M, Sixou M, Burcelin R. [Impact of periodontal disease on arterial pressure in diabetic mice]. Ann Cardiol Angeiol (Paris) 2012; 61:173-177. [PMID: 22621847 DOI: 10.1016/j.ancard.2012.04.012] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2012] [Accepted: 04/15/2012] [Indexed: 06/01/2023]
Abstract
Diabetes-driven cardiovascular diseases represent a high challenge for developed countries. Periodontal disease is strictly linked to the aforementioned diseases, due to its Gram negative-driven inflammation. Thus, we investigated the effects of periodontal disease on arterial pressure during the development of diabetes in mice. To this aim, C57BL/6 female mice were colonized with pathogens of periodontal tissue (Porphyromonas gingivalis, Prevotella intermedia and Fusobacterium nucleatum) for 1month, whereas another group of mice did not undergo the colonization. Subsequently, all mice were fed a high-fat carbohydrate-free diet for 3months. Then, arterial pressure was measured in vivo and a tomodensitometric analysis of mandibles was realized as well. Our results show increased mandibular bone-loss induced by colonization with periopathogens. In addition, periodontal infection augmented glucose-intolerance and systolic and diastolic arterial pressure, parameters already known to be affected by a fat-diet. In conclusion, we show here that periodontal disease amplifies metabolic troubles and deregulates arterial pressure, emerging as a new axis of metabolic investigation.
Collapse
Affiliation(s)
- V Blasco-Baque
- Parodontites et maladies générales LU 51, faculté de chirurgie dentaire, 3, chemin des Maraîchers, 31062 Toulouse cedex, France.
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Serino M, Luche E, Gres S, Baylac A, Bergé M, Cenac C, Waget A, Klopp P, Iacovoni J, Klopp C, Mariette J, Bouchez O, Lluch J, Ouarné F, Monsan P, Valet P, Roques C, Amar J, Bouloumié A, Théodorou V, Burcelin R. Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut 2012; 61:543-53. [PMID: 22110050 PMCID: PMC3292714 DOI: 10.1136/gutjnl-2011-301012] [Citation(s) in RCA: 440] [Impact Index Per Article: 36.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
OBJECTIVE The gut microbiota, which is considered a causal factor in metabolic diseases as shown best in animals, is under the dual influence of the host genome and nutritional environment. This study investigated whether the gut microbiota per se, aside from changes in genetic background and diet, could sign different metabolic phenotypes in mice. METHODS The unique animal model of metabolic adaptation was used, whereby C57Bl/6 male mice fed a high-fat carbohydrate-free diet (HFD) became either diabetic (HFD diabetic, HFD-D) or resisted diabetes (HFD diabetes-resistant, HFD-DR). Pyrosequencing of the gut microbiota was carried out to profile the gut microbial community of different metabolic phenotypes. Inflammation, gut permeability, features of white adipose tissue, liver and skeletal muscle were studied. Furthermore, to modify the gut microbiota directly, an additional group of mice was given a gluco-oligosaccharide (GOS)-supplemented HFD (HFD+GOS). RESULTS Despite the mice having the same genetic background and nutritional status, a gut microbial profile specific to each metabolic phenotype was identified. The HFD-D gut microbial profile was associated with increased gut permeability linked to increased endotoxaemia and to a dramatic increase in cell number in the stroma vascular fraction from visceral white adipose tissue. Most of the physiological characteristics of the HFD-fed mice were modulated when gut microbiota was intentionally modified by GOS dietary fibres. CONCLUSIONS The gut microbiota is a signature of the metabolic phenotypes independent of differences in host genetic background and diet.
Collapse
Affiliation(s)
- Matteo Serino
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| | - Elodie Luche
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| | - Sandra Gres
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| | - Audrey Baylac
- Université de Toulouse III, UPS, LU49, Adhésion Bactérienne et Formation de Biofilms, Toulouse Cedex 9, France
| | - Mathieu Bergé
- Université de Toulouse III, UPS, LU49, Adhésion Bactérienne et Formation de Biofilms, Toulouse Cedex 9, France
| | - Claire Cenac
- Neuro-Gastroenterology and Nutrition Unit, UMR INRA/EI-Purpan, Toulouse Cedex 3, France
| | - Aurelie Waget
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| | - Pascale Klopp
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| | - Jason Iacovoni
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| | - Christophe Klopp
- Plateforme Bio-informatique Toulouse Genopole®, UBIA INRA, Castanet-Tolosan Cedex, France
| | - Jerome Mariette
- Plateforme Bio-informatique Toulouse Genopole®, UBIA INRA, Castanet-Tolosan Cedex, France
| | - Olivier Bouchez
- GENOTOUL Platform, INRA Chemin de Borde-Rouge, Auzeville, France
| | - Jerome Lluch
- GENOTOUL Platform, INRA Chemin de Borde-Rouge, Auzeville, France
| | - Francoise Ouarné
- Université de Toulouse III, INSA, UPS, INP, LISBP, Toulouse, France
| | - Pierre Monsan
- Université de Toulouse III, INSA, UPS, INP, LISBP, Toulouse, France,CNRS, UMR5504, Toulouse, France,INRA, UMR792 Ingénierie des Systèmes Biologiques et des Procédés, Toulouse, France,Institut Universitaire de France, Paris, France
| | - Philippe Valet
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| | - Christine Roques
- Université de Toulouse III, UPS, LU49, Adhésion Bactérienne et Formation de Biofilms, Toulouse Cedex 9, France
| | - Jacques Amar
- Rangueil Hospital, Department of Therapeutics, Toulouse, France
| | - Anne Bouloumié
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| | - Vassilia Théodorou
- Neuro-Gastroenterology and Nutrition Unit, UMR INRA/EI-Purpan, Toulouse Cedex 3, France
| | - Remy Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| |
Collapse
|
47
|
Moreno-Navarrete JM, Ortega F, Serino M, Luche E, Waget A, Pardo G, Salvador J, Ricart W, Frühbeck G, Burcelin R, Fernández-Real JM. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes (Lond) 2011; 36:1442-9. [PMID: 22184060 DOI: 10.1038/ijo.2011.256] [Citation(s) in RCA: 152] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVE Lipopolysaccharide-binding protein (LBP) is a 65-kDa acute-phase protein present in blood at high concentrations, known to be derived from the liver. We aimed to gain insights into the association of circulating LBP with insulin resistance in humans and mice. METHODS, DESIGN AND MEASUREMENTS: We studied the cross-sectional (n=222) and weight loss-induced (n=34) associations of LBP (enzyme-linked immunosorbent assay) with inflammatory and metabolic parameters (including minimal model-measured insulin sensitivity), and the effects of high-fat diet (HFD), metformin and genetic insulin sensitization (glucagon-like peptide 1 receptor knockout model) in mice. RESULTS Circulating LBP concentration was significantly increased in subjects with type 2 diabetes and dramatically increased in subjects with morbid obesity. LBP was significantly associated with insulin sensitivity and different inflammatory markers and decreased after weight loss (22.2 ± 5.8 vs 16.2 ± 9.3 μg ml(-1), P<0.0001) in association with changes in body mass index and insulin sensitivity. Circulating LBP concentration was increased in HFD mice, whereas decreased in glucagon-like peptide 1 receptor knockout mice (significantly more insulin sensitive than wild-type mice) and after metformin administration. CONCLUSION LBP is an inflammatory marker associated with obesity-related insulin resistance.
Collapse
Affiliation(s)
- J M Moreno-Navarrete
- Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), Girona, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Abstract
More than several hundreds of millions of people will be diabetic and obese over the next decades in front of which the actual therapeutic approaches aim at treating the consequences rather than causes of the impaired metabolism. This strategy is not efficient and new paradigms should be found. The wide analysis of the genome cannot predict or explain more than 10-20% of the disease, whereas changes in feeding and social behavior have certainly a major impact. However, the molecular mechanisms linking environmental factors and genetic susceptibility were so far not envisioned until the recent discovery of a hidden source of genomic diversity, i.e., the metagenome. More than 3 million genes from several hundreds of species constitute our intestinal microbiome. First key experiments have demonstrated that this biome can by itself transfer metabolic disease. The mechanisms are unknown but could be involved in the modulation of energy harvesting capacity by the host as well as the low-grade inflammation and the corresponding immune response on adipose tissue plasticity, hepatic steatosis, insulin resistance and even the secondary cardiovascular events. Secreted bacterial factors reach the circulating blood, and even full bacteria from intestinal microbiota can reach tissues where inflammation is triggered. The last 5 years have demonstrated that intestinal microbiota, at its molecular level, is a causal factor early in the development of the diseases. Nonetheless, much more need to be uncovered in order to identify first, new predictive biomarkers so that preventive strategies based on pre- and probiotics, and second, new therapeutic strategies against the cause rather than the consequence of hyperglycemia and body weight gain.
Collapse
Affiliation(s)
- Rémy Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1048, Toulouse, France.
- Université de Toulouse, UPS, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), 31432, Toulouse cedex 4, France.
| | - Matteo Serino
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1048, Toulouse, France
- Université de Toulouse, UPS, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), 31432, Toulouse cedex 4, France
| | - Chantal Chabo
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1048, Toulouse, France
- Université de Toulouse, UPS, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), 31432, Toulouse cedex 4, France
| | - Vincent Blasco-Baque
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1048, Toulouse, France
- Université de Toulouse, UPS, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), 31432, Toulouse cedex 4, France
| | - Jacques Amar
- Department of Therapeutics, Rangueil Hospital, Toulouse, France
| |
Collapse
|
49
|
Amar J, Serino M, Lange C, Chabo C, Iacovoni J, Mondot S, Lepage P, Klopp C, Mariette J, Bouchez O, Perez L, Courtney M, Marre M, Klopp P, Lantieri O, Doré J, Charles MA, Balkau B, Burcelin R. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia 2011; 54:3055-61. [PMID: 21976140 DOI: 10.1007/s00125-011-2329-8] [Citation(s) in RCA: 205] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2011] [Accepted: 09/09/2011] [Indexed: 10/17/2022]
Abstract
AIMS/HYPOTHESIS Evidence suggests that bacterial components in blood could play an early role in events leading to diabetes. To test this hypothesis, we studied the capacity of a broadly specific bacterial marker (16S rDNA) to predict the onset of diabetes and obesity in a general population. METHODS Data from an Epidemiological Study on the Insulin Resistance Syndrome (D.E.S.I.R.) is a longitudinal study with the primary aim of describing the history of the metabolic syndrome. The 16S rDNA concentration was measured in blood at baseline and its relationship with incident diabetes and obesity over 9 years of follow-up was assessed. In addition, in a nested case-control study in which participants later developed diabetes, bacterial phylotypes present in blood were identified by pyrosequencing of the overall 16S rDNA gene content. RESULTS We analysed 3,280 participants without diabetes or obesity at baseline. The 16S rDNA concentration was higher in those destined to have diabetes. No difference was observed regarding obesity. However, the 16S rDNA concentration was higher in those who had abdominal adiposity at the end of follow-up. The adjusted OR (95% CIs) for incident diabetes and for abdominal adiposity were 1.35 (1.11, 1.60), p = 0.002 and 1.18 (1.03, 1.34), p = 0.01, respectively. Moreover, pyrosequencing analyses showed that participants destined to have diabetes and the controls shared a core blood microbiota, mostly composed of the Proteobacteria phylum (85-90%). CONCLUSIONS/INTERPRETATION 16S rDNA was shown to be an independent marker of the risk of diabetes. These findings are evidence for the concept that tissue bacteria are involved in the onset of diabetes in humans.
Collapse
Affiliation(s)
- J Amar
- Inserm U1027, University Paul Sabatier, CHU, Hôpital Rangueil, Avenue Jean Pouhles, Toulouse, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Blasco-Baque V, Kemoun P, Loubieres P, Arnal JF, Gourdy P, Serino M, Burcelin R, Sixou M. Impact of type 2 diabetes on the development of periodontal disease in the mouse. Bull Group Int Rech Sci Stomatol Odontol 2011; 50:11-12. [PMID: 22750698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Received: 11/22/2011] [Accepted: 11/22/2011] [Indexed: 06/01/2023]
Affiliation(s)
- V Blasco-Baque
- Parodontites et maladies générales L.U. 46 Faculté de chirurgie dentaire, 3 chemin des Maraîchers, Toulouse Cedex, France.
| | | | | | | | | | | | | | | |
Collapse
|